,id,ticker,title,category,content,date,provider,url,article_id
4172,225687,ARQL,Merck begins tender offer to acquire Arqule,news,"Merck  NYSE MRK  commences a cash tender offer to purchase all outstanding common shares of ArQule  NASDAQ ARQL   Upon closing of the tender offer  stockholders of ArQule will receive  20 in cash for each common share  following which ArQule will become a wholly owned subsidiary of Merck 
Merck will file with the SEC a tender offer statement on Schedule TO  which provides the terms of the tender offer  The tender offer will expire on January 15  2020 
Previously  ArQule up 101  premarket on Merck bid  Dec  9 ",2019-12-17,Seeking Alpha,https://invst.ly/p4rbi,2042871
4173,225688,ARQL,ArQule  ARQL  Catches Eye  Stock Jumps 8 1   ,opinion,ArQule  Inc    NASDAQ ARQL   was a big mover last session  as the company saw its shares rise more than 8  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  6 24 to  10 49 in the past one month time frame The company has seen two negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last  ArQule currently has a Zacks Rank  3  Hold  while its  is negative   ArQule  Inc  Price   Investors interested in the Medical   Drugs industry may consider Neos Therapeutics  Inc    NASDAQ NEOS    which has a Zacks Rank  1  Strong Buy   You can see Is ARQL going up  Or down  Predict to see what others think Up or DownMore Stock News  This Is Bigger than the iPhone  It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market  Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/arqule-arql-catches-eye-stock-jumps-81-200434831,200434831
4174,225689,ARQL,ArQule  ARQL  To Post Q2 Earnings  What s In The Cards ,opinion,ArQule  Inc    NASDAQ ARQL   is scheduled to report second quarter 2019 results on Aug 7  before the market opens The company s earnings record has been mixed so far  having delivered a positive surprise in two of the last four quarters  missing expectations once while delivering in line results on another occasion  The average four quarter beat is 38 54   In the last reported quarter  ArQule came up with a negative surprise of 12 50  Shares of ArQule have skyrocketed 241 9  so far this year compared with the  rally of 7 2  Let s see how things are shaping up for this announcement Factors to ConsiderArQule does not have any approved product in its portfolio at the moment  As a result  the company is yet to generate any revenues ArQule is developing ARQ 531  currently in phase I study for treating patients with BTK mutated B cell malignancies refractory to other therapeutic options  The candidate is a potent and reversible dual inhibitor of both wild type and C481S mutant BTK  In June  the company presented preliminary results from this early stage study on ARQ 531 for treating patients with relapsed or refractory hematologic malignancies  at the annual meeting of European Hematology Association  ARQ 531 demonstrated substantial anti tumor activity and a favorable safety profile Meanwhile  ArQule received the first conditional Institutional Review Board  IRB  approval for miransertib  its investigational AKT inhibitor  The company plans to begin a registrational clinical study on the same for treating Proteus syndrome and PIK3CA Related Overgrowth Spectrum  PROS  family of rare overgrowth diseases  An IRB approval is required before commencing research projects involving human subjects Derazantinib  an FGFR inhibitor  is currently in a registrational clinical study for treating intrahepatic cholangiocarcinoma in patients with FGFR2 fusions  Notably  ArQule out licensed derazantinib rights to Switzerland s Basilea Pharmaceutica last April to develop commercialize derazantinib in the United States  European Union  Japan and the rest of the world excluding Greater China We expect management to provide a thorough update on the company s pipeline during the upcoming earnings call Earnings WhispersOur proven model does not conclusively show that ArQule is likely to beat estimates this quarter to be reported  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  ArQule has an Earnings ESP of  5 56   representing the percentage difference between the Most Accurate Estimate of a loss of 10 cents and the Zacks Consensus Estimate of a loss of 9 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  ArQule has a Zacks Rank  3  which increases the predictive power of ESP  However  its negative ESP in the combination leaves surprise prediction inconclusive We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions ArQule  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are some biotech stocks worth considering as our model shows that these have the right mix of elements to beat on earnings this reporting cycle BeiGene  Ltd    NASDAQ BGNE   has a Zacks Rank of 1 and an Earnings ESP of  8 55   You can see  Intec Pharma Ltd    NASDAQ NTEC   has an Earnings ESP of  7 14  and a Zacks Rank  2 Puma Biotechnology  Inc    NASDAQ PBYI   has a Zacks Rank of 3 and an Earnings ESP of  1 11   The company is scheduled to release second quarter results on Aug 8  after the market closes The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/arqule-arql-to-post-q2-earnings-whats-in-the-cards-200451616,200451616
4175,225690,ARQL,U S  stocks lower at close of trade  Dow Jones Industrial Average down 0 38 ,news,"Investing com   U S  stocks were lower after the close on Monday  as losses in the Healthcare  Utilities and Telecoms sectors led shares lower 
At the close in NYSE  the Dow Jones Industrial Average fell 0 38   while the S P 500 index declined 0 32   and the NASDAQ Composite index fell 0 40  
The best performers of the session on the Dow Jones Industrial Average were  Home Depot  Inc  NYSE HD   which rose 1 05  or 2 25 points to trade at 216 53 at the close  Meanwhile  Procter   Gamble Company  NYSE PG  added 0 55  or 0 68 points to end at 124 87 and International Business Machines  NYSE IBM  was up 0 53  or 0 70 points to 133 92 in late trade 
The worst performers of the session were Apple Inc  NASDAQ AAPL   which fell 1 40  or 3 79 points to trade at 266 92 at the close   Goldman Sachs Group  Inc  NYSE GS  declined 1 25  or 2 80 points to end at 221 81 and Walt  Disney  Company  NYSE DIS  was down 0 98  or 1 45 points to 146 21 
The top performers on the S P 500 were  Nektar Therapeutics   NASDAQ NKTR  which rose 13 03  to 23 11  Freeport McMoran Copper   Gold Inc  NYSE FCX  which was up 3 95  to settle at 12 10 and  Nordstrom Inc   NYSE JWN  which gained 3 59  to close at 38 91 
The worst performers were International Flavors   Fragrances Inc  NYSE IFF  which was down 5 79  to 133 81 in late trade   ABIOMED  Inc  NASDAQ ABMD  which lost 3 98  to settle at 181 69 and Ulta Beauty Inc  NASDAQ ULTA  which was down 3 65  to 252 64 at the close 
The top performers on the NASDAQ Composite were  Synthorx  Inc  NASDAQ THOR  which rose 170 52  to 67 71   Forty Seven  Inc  NASDAQ FTSV  which was up 110 73  to settle at 30 43 and  ArQule  Inc  NASDAQ ARQL  which gained 103 88  to close at 19 705 
The worst performers were  Precision BioSciences Inc   NASDAQ DTIL  which was down 51 68  to 9 50 in late trade  Biocept Inc  NASDAQ BIOC  which lost 49 99  to settle at 0 270 and  ObsEva SA   NASDAQ OBSV  which was down 29 32  to 3 23 at the close 
Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1398 to 1386 and 103 ended unchanged  on the Nasdaq Stock Exchange  1500 fell and 1145 advanced  while 84 ended unchanged 
Shares in Synthorx Inc  NASDAQ THOR  rose to all time highs  rising 170 52  or 42 68 to 67 71  Shares in Forty Seven Inc  NASDAQ FTSV  rose to all time highs  up 110 73  or 15 99 to 30 43  Shares in Biocept Inc  NASDAQ BIOC  fell to all time lows  falling 49 99  or 0 270 to 0 270  Shares in ArQule Inc  NASDAQ ARQL  rose to 5 year highs  gaining 103 88  or 10 040 to 19 705  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was up 16 45  to 15 86 
Gold Futures for February delivery was up 0 06  or 0 85 to  1465 95 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 0 49  or 0 29 to hit  58 91 a barrel  while the February Brent oil contract unchanged 0 00  or 0 00 to trade at  64 06 a barrel 
EUR USD was up 0 02  to 1 1064  while USD JPY rose 0 01  to 108 56 
The US Dollar Index Futures was down 0 04  at 97 620 ",2019-12-09,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-lower-at-close-of-trade-dow-jones-industrial-average-down-038-2037400,2037400
4191,225706,ARQL,5 Charts To Watch  ARQL  HROW  PYX  WKHS  XNCR,opinion,"It was another really bad day on Wall Street on Tuesday  but the technicals weren t as bad as the price looked  I don t know what that means yet  but we ll see  A lot of the stocks we follow may  or are  swinging  In the meantime  let s take a look at a few we highlighted here along with the charts 
ArQule  Inc   ARQL 
ARQL is in a beautiful uptrend  It had the breakaway move a week and a half ago  and now it s in a beautiful rising channel or flag  On Tuesday  it was up 81 cents or 8   to 10 82  on nearly 13 million shares  That s a significant increase in volume  If it could get through resistance  it could blow  It s at the highest level in 17 years  The next target has to be up around 11 1 2  and 13  Keep your eye on this one going forward 
Harrow Health  Inc   HROW 
HROW has been up for nine days in a row  On Tuesday  it popped 35 cents  or 4 62   to 7 92  on 652 442 shares traded  The volume is excellent and it did break out  I m still looking for more upside to 9 9 1 2 10 before it pulls back  At least that appears to be what is happening 
Pyxus International  Inc   PYX 
PYX has a new swing I put on it on Tuesday  It had a nice pop of 3 61  or 27   to 17 04  on 3 4 million shares  That s huge volume for a stock that averages 638 681  I m looking for a test around 20 1 2 21  If it gets through that  I m looking at targets at 23 1 2  and then 26 
Workhorse Group Inc   WKHS 
WKHS is looking well  It had a large ascending wedge after an explosive move in May and has a flag that really looks juicy  It popped out of the wedge to gain 21 cents  or 8   to 2 85  on 3 7 million shares  I think this stock is going to make a run at 3 3 3 4  If it gets through that  3 3 3 4  and then 5  are our targets 
Xencor  Inc   XNCR 
XNCR has spent about nine months consolidating in a declining channel  It popped out and retested  forming a base  and then had a breakaway gap on Tuesday of 4 69  or 14   to 38 56  on 1 9 million shares  That is massive volume for this stock  It tells me it needs to break out and run  The next target is 43  and then  ultimately  a retest of the high at 48 is my target 
Stocks on the long side included ArQule  Inc   ARQL   Dova Pharmaceuticals  Inc   DOVA   e l f  Beauty  Inc   ELF   Harrow Health  Inc   HROW   Hydrogenics Corporation  HYGS   MeiraGTx Holdings  MGTX   Melinta Therapeutics  Inc   MLNT   Natera  Inc   NTRA   Pyxus International  Inc   PYX   Riot Blockchain  Inc   RIOT   Workhorse Group Inc   WKHS   and Xencor  Inc   XNCR  
Watch Video Here",2019-06-26,Harry Boxer,https://www.investing.com/analysis/arql-hrow-pyx-wkhs-xncr--stock-charts-to-watch-200434710,200434710
4193,225708,ARQL,Options Traders Expect Huge Moves In ArQule  ARQL  Stock  ,opinion,Investors in ArQule  Inc    NASDAQ ARQL   need to pay close attention to the stock based on moves in the options market lately  That is because the Jun 15  2018  7 50 Call had some of the highest implied volatility of all equity options today What is Implied Volatility Implied volatility shows how much movement the market is expecting in the future  Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other  It could also mean there is an event coming up soon that may cause a big rally or a huge sell off  However  implied volatility is only one piece of the puzzle when putting together an options trading strategy What do the Analysts Think Clearly  options traders are pricing in a big move for ArQule shares  but what is the fundamental picture for the company  Currently  ArQule is a Zacks Rank  3  Hold  in the Medical   Drugs industry that ranks in the Top 40  of our Zacks Industry Rank  Over the last 60 days  one analyst has increased the earnings estimate for the current quarter  while none have dropped their estimates  The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 9 cents per share to a loss of 5 cents in that period Given the way analysts feel about ArQule right now  this huge implied volatility could mean there s a trade developing  Oftentimes  options traders look for options with high levels of implied volatility to sell premium  This is a strategy many seasoned traders use because it captures decay  At expiration  the hope for these traders is that the underlying stock does not move as much as originally expected Looking to Trade Options Each week  our very own Dave Bartosiak gives his top options trades  Check out his recent live analysis and options trade for the NFLX earnings report completely free  See it here   or check out the embedded video below for more details ,2018-06-11,Zacks Investment Research,https://www.investing.com/analysis/options-traders-expect-huge-moves-in-arqule-arql-stock-200323811,200323811
4194,225709,ARQL,4 Stocks To Watch  CRSP  I  TNDM  VRNS,opinion,"CRISPR Therapeutics AG  NASDAQ CRSP  made a big move on Wednesday  jumping 5 81  or 9   to 69 57  1 9 million shares  It has gone from 47 to 69 in the last two weeks  The pause and then two days on lower volume gave it the momentum to pop back up on volume again  Mid channel line is right about 75  That is my target  and eventually I think it will work it s way higher 
Intelsat S A   NYSE I  has made another phenomenal move breaking out of a wedge on Wednesday  and gaining 1 76  or 12   to 16 30  on 4 77 million shares  It looks like it s headed to 20 21 
Tandem Diabetes Care  Inc   NASDAQ TNDM  is still running up  What a beautiful chart this one is  with a rising flag on Wednesday  taking it up another 74 cents  or 5 69   to 13 75  on 2 2 million shares  Volume is steady   is steady  I would not be shocked if this stock made it all the way up to my 16 17 target zone 
Varonis Systems  Inc   NASDAQ VRNS   one of our old swings from back in May of last year  and it is still running  going from the low 30 s to the mid 70 s  It jumped 2 20  or 3   to 74 90  on 213 338 shares traded on Wednesday  I think it has further to go and is eventually an 85 dollar stock 
Stocks on the long side included ArQule  Inc   NASDAQ ARQL   Baozun Inc   NASDAQ BZUN   Cara Therapeutics  Inc   NASDAQ CARA   CRISPR Therapeutics AG  NASDAQ CRSP   eGain Corporation  NASDAQ EGAN   Evolus  Inc   NASDAQ EOLS   Geron Corporation  NASDAQ GERN   Turtle Beach Corporation  NASDAQ HEAR   Intelsat S A   I   Immunomedics  Inc   NASDAQ IMMU   Mirati Therapeutics  Inc   NASDAQ MRTX   Minerva Neurosciences  Inc   NASDAQ NERV   Quantenna Communications  Inc   NASDAQ QTNA   Sea Limited  NYSE SE   Tandem Diabetes Care  Inc   NASDAQ TNDM   Canopy Growth Corporation  OTC TWMJF   USA Technologies  Inc   NASDAQ USAT   21Vianet Group  Inc   NASDAQ VNET   Varonis Systems  Inc   NASDAQ VRNS   and Xencor  Inc   NASDAQ XNCR  ",2018-05-24,Harry Boxer,https://www.investing.com/analysis/crsp-i-tndm-vrns-200318887,200318887
4205,225720,ARQL,ValuEngine Upgrades Etsy To Strong Buy ,opinion,"For today s edition of our upgrade list  we used our website s advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data  They are presented by one month forecast return 

ArQule Inc  NASDAQ ARQL  and Etsy Inc  NASDAQ ETSY  are rated STRONG BUY 
The rest of our upgrades for today are rated BUY 


Etsy  Inc   ETSY  offers e commerce services  It provides online and offline marketplaces to buy and sell goods  The company s product include art  home and living  mobile accessories  jewelry  wedding  and others  It operates primarily in Berlin  Germany  Dublin  Ireland  Hudson  New York  London  United Kingdom  Melbourne  Australia  Paris  France  San Francisco  California and Toronto  Canada  Etsy  Inc  is headquartered in Brooklyn  New York 
Etsy has been on a run lately  with the stock up almost 5  over the past 30 days and hitting a new 52 week high this week  For the year  the shares are up more than 60  
The company posted decent results last month  with Q1 total revenue of  120 9 million  up 24 8  year over year  driven by growth in both Marketplace and Services revenue  Marketplace revenue grew 24 7  year over year  driven by growth in Etsy Payments  Services revenue grew 35 0  year over year  driven primarily by revenue growth in Promoted Listings  and  to a lesser extent  Etsy Shipping Labels 
Gross profit for the first quarter of 2018 was  79 6 million   up 27 9  year over year and gross margin was 65 8   up 160 basis points compared with 64 2  in the first quarter of 2017  Net income for the first quarter of 2018 was  13 0 million   with diluted earnings per share of  0 10   compared with a net loss of  0 4 million and a net loss per share of  0 00 in the first quarter of 2017 
ValuEngine updated its recommendation from BUY to STRONG BUY for ETSY INC on 2018 06 05  Based on the information we have gathered and our resulting research  we feel that ETSY INC has the probability to OUTPERFORM average market performance for the next year  The company exhibits ATTRACTIVE Momentum and Company Size 
You can download a free copy of detailed report on Etsy  Inc   ETSY  from the link below ",2018-06-07,Steve Hach,https://www.investing.com/analysis/valuengine-upgrades-etsy-to-strong-buy-200322802,200322802
4209,225724,ARQL,Forget Valeant  Invest In These Attractive Drug Stocks Instead,opinion,"Once an acquisition giant  Canada based Valeant Pharmaceuticals   NYSE VRX   has been in the spotlight since the second half of 2015 for all the wrong reasons like a price hike of specialty drugs  erroneous financial reporting  and termination of contracts with Philidor Rx Services  The going got worse in the first half of 2016 leading to a massive decline in its share prices 
Further  Valeant delayed its first quarter earnings release due to the review of certain accounting practices  which led to a notice of default from its debtors  As if the delayed results and the ensuing notice were not enough  the company slashed its annual guidance when it announced its first quarter results earlier this month  dampening investor sentiments even more  In addition  management transition issues  heavy debt levels and persistent organizational distractions continue to plague the company VALEANT PHARMA Price and Consensus
   Even though the new CEO  Joseph Papa has set out to rebuild the company in the wake of the catastrophe  regaining investor trust is going to be a Herculean task  In this scenario  it s probably best to forget Valeant and instead invest in some other drug stocks with a favorable Zacks Rank  They also have healthy pipelines products and strong growth potential 
Our Picks
Massachusetts based ArQule  Inc    NASDAQ ARQL   is a biopharmaceutical company engaged in the research and development of innovative therapeutics for the treatment of cancers and rare diseases  The company s lead candidate  tivantinib  ARQ 197   is being evaluated for the treatment of liver cancer  It is currently conducting two phase III trials on the candidate with its partners  Daiichi Sankyo Co   Ltd  and Kyowa Hakko Kirin Co   Ltd 
The company s pipeline also includes candidates like ARQ 092  which is being developed for multiple oncology indications as well as for Proteus syndrome  ARQ 087 for the treatment of intrahepatic cholangiocarcinoma  iCCA  as well as for multiple oncology indications  and another oncology candidate  ARQ 761  ArQule s pipeline looks pretty interesting at this point  with the company progressing on tivantinib  The company currently carries a Zacks Rank  2  Buy  ARQULE INC Price and Consensus
   Coral Gables  FL based Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   is a biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert Eaton myasthenic syndrome  LEMS   epilepsy  initially infantile spasms  and Tourette syndrome  The company has three drug candidates in development   Firdapse  CPP 115 and CPP 109  Catalyst in licensed rights to Firdapse from BioMarin 
Firdapse has already suffered its share of setbacks  but things look relatively better now  The recent meeting with the FDA on a confirmatory phase III study protocol for Firdapse should reduce any additional delay in Firdapse s development  The stock currently has a Zacks Rank  2 CATALYST PHARMA Price and Consensus
   Washington based OncoGenex Pharmaceuticals  Inc    NASDAQ OGXI   is a developmental stage biopharmaceutical company that focuses on developing therapies for cancer  The company s pipeline  which comprises custirsen  apatorsen and OGX 225  looks pretty interesting  Among these  the focus is on custirsen  a late stage candidate that is being developed for the treatment of metastatic castrate resistant prostate cancer  CRPC  and non small cell lung cancer  NSCLC  
Custirsen has been granted Fast Track designation by the FDA for the second line treatment of both metastatic CRPC and advanced NSCLC  The stock currently carries a Zacks Rank  2 ONCOGENEX PHARM Price and Consensus
   Headquartered at Henderson  NV  biotechnology company Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   develops and commercializes oncology and hematology drug products  The company has six approved oncology hematology products targeting various types of non Hodgkin s lymphoma  NHL   advanced metastatic colorectal cancer  acute lymphoblastic leukemia  ALL  and multiple myeloma  MM   
The company also has three late stage candidates in its pipeline   SPI 2012 for chemotherapy induced neutropenia in patients with breast cancer  Eoquin for immediate intravesical instillation in post transurethral resection of bladder tumors in patients with non muscle invasive bladder cancer and poziotinib for breast cancer 
The company s progress on its pipeline candidates is impressive  In Mar 2016  the FDA approved its oncology drug  Evomela  two months ahead of the PDUFA date  The company expects a response from the FDA on its NDA for Eoquin later this year   The stock currently carries a Zacks Rank  2 SPECTRUM PHARMA Price and Consensus
  ",2016-06-28,Zacks Investment Research,"https://www.investing.com/analysis/forget-valeant,-invest-in-these-attractive-drug-stocks-instead-200138796",200138796
4210,225725,ARQL,Tesaro Gets Fast Track Designation For Ovarian Cancer Drug,opinion,"Tesaro  Inc    NASDAQ TSRO   announced that the FDA has granted Fast Track designation to its pipeline candidate  niraparib  for the treatment of patients with recurrent platinum sensitive ovarian  fallopian tube  or primary peritoneal cancer Tesaro has initiated a rolling submission of a New Drug Application  NDA  for niraparib to the FDA  The company plans to complete the submission during the fourth quarter of 2016 The FDA s Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious conditions and address unmet medical needs As part of the Fast Track program  the FDA allows for the submission of completed portions of an NDA on an ongoing or rolling basis  Tesaro is also planning to submit a Marketing Authorisation Application  MAA  for niraparib with the European Medicines Agency  EMA  in the fourth quarter TESARO INC Price and Consensus
    We note that Tesaro is currently evaluating niraparib in four ongoing trials   a phase III trial  NOVA  in patients with platinum sensitive  recurrent ovarian cancer  a phase III trial  PRIMA  in patients with first line ovarian cancer  a registrational phase II trial  QUADRA  in patients with ovarian cancer  and a phase III trial  BRAVO  in patients with BRCA positive breast cancer The company plans to present data from NOVA at a medical summit next month  The trial enrolled more than 500 patients with recurrent ovarian cancer  who were in response to their most recent platinum based chemotherapy We note that the FDA approved Tesaro s first commercial product  Varubi  for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in Sep 2015 Tesaro currently carries a Zacks Rank  3  Hold   Investors interested in the healthcare sector may consider stocks like ArQule Inc    NASDAQ ARQL    Pacira Pharmaceuticals   NASDAQ PCRX   and ANI Pharmaceuticals   NASDAQ ANIP    While Pacira and ANI Pharma sport a Zacks Rank  1  Strong Buy   ArQule is a Zacks Rank  2  Buy  stock 
You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-13,Zacks Investment Research,https://www.investing.com/analysis/tesaro-gets-fast-track-designation-for-ovarian-cancer-drug-200153349,200153349
4211,225726,ARQL,Can The Uptrend Continue For ArQule  ARQL  ,opinion,"Investors certainly have to be happy with ArQule Inc    NASDAQ ARQL   and its short term performance  After all  the stock has jumped by 19 6  in the past 4 weeks  and it is also above its 20 Day Simple Moving Average as well  This is certainly a good trend  but investors are probably asking themselves  can this positive trend continue for ARQL 
While we can never know for sure  it is pretty encouraging that estimates for ARQL have moved higher in the past few weeks  meaning that analyst sentiment is moving in the right way  Plus  the stock actually has a Zacks Rank  2  Buy   so the recent move higher for this spotlighted company may definitely continue over the next few weeks 
Confidential from Zacks
Beyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-27,Zacks Investment Research,https://www.investing.com/analysis/can-the-uptrend-continue-for-arqule-(arql)-200156088,200156088
4212,225727,ARQL,Galectin Therapeutics  GALT  Jumps  Stock Rises 15 1 ,opinion,"Galectin Therapeutics Inc    NASDAQ GALT   was a big mover last session  as the company saw its shares rise more than 15  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  1 54 to  2 98 in the past one month time frame The company has seen three positive estimate revisions in the past few months  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months  suggesting that more solid trading could be ahead for Galectin Therapeutics  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road 
Galectin Therapeutics currently has a Zacks Rank  3  Hold  while its is positive 
Galectin Therapeutics Inc  Price   A better ranked stock worth considering in the Medical sectoris ArQule  Inc    NASDAQ ARQL   which carries a Zacks Rank  2  Buy  You can see  Is GALT going up  Or down  Predict to see what others think  or  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-12-27,Zacks Investment Research,https://www.investing.com/analysis/galectin-therapeutics-galt-jumps-stock-rises-151-200276313,200276313
4213,225728,ARQL,4 Stocks To Watch  ANF  COLL  FIVN  VIPS,opinion,"Abercrombie   Fitch Co   NYSE ANF  continues to look great  jumping another 1 10  or 4 73   to 24 35  on 2 35 million shares on Monday  This swing trade  which we put on it in November at the big breakaway gap  steadily moved up  wedged  popped  came down in a falling wedge  popped out of that  The highest close it s had recently lines up with a close two years ago in May at 24 35  Although there may be some minor resistance in the area just above it  I think it s headed to 28  30  maybe ever 32 and 33 
Collegium Pharmaceutical  Inc   NASDAQ COLL  looks to me like it s breaking out again  It popped 1 19  or 4 48   to 27 73  on 387 337 shares traded on Monday  It needs some volume  and again  it needs to get over 29 29  30  If it does  it could run into the mid 30 s  maybe the 34 36 range 
Five9  Inc   NASDAQ FIVN   one of my Top 25  broke out of its base with a breakaway gap  it formed a wedge  and has been wedging  On Monday  it popped 1 22  or 4   to 31 57  on nearly 300 000 shares traded  I think this stock is designed to get into the mid 30 s  and then maybe 40 
Vipshop Holdings Limited  NYSE VIPS  ripped right back on Monday  bouncing 1 00  or 5 88   to 18 00  on nearly 9 million shares  There s big resistance here  so watch that level going forward around 19  If it gets through that  it should see 22 
Stocks on the long side included Baozun Inc   NASDAQ BZUN   Five9  Inc   FIVN   Abercrombie   Fitch Co   ANF   Fate Therapeutics  Inc   NASDAQ FATE   Chegg  Inc   NYSE CHGG   eGain Corporation  NASDAQ EGAN   Xencor  Inc   NASDAQ XNCR   SMART Global Holdings  Inc   NASDAQ SGH   ImmunoGen  Inc   NASDAQ IMGN   MongoDB  Inc   NASDAQ MDB   Geron Corporation  NASDAQ GERN   Vipshop Holdings Limited  NYSE VIPS   PGT  Inc   NYSE PGTI   ArQule  Inc   NASDAQ ARQL   Legacy Reserves LP  NASDAQ LGCY   ShotSpotter  Inc   NASDAQ SSTI   Versum Materials  Inc   NYSE VSM   Collegium Pharmaceutical  Inc   NASDAQ COLL  
Below you find the video  ",2018-03-26,Harry Boxer,https://www.investing.com/analysis/anf-coll-fivn-vips-200300896,200300896
4214,225729,ARQL,Premarket Losers as of 9 05 am  07 10 2018 ,news,BLIN  11   RSLS  12  on direct offering  BDR  12   IOTS  10  on pricing public offering of common stock  MFGP  11  on interim results  SAR  8  after stock offering prices  GBR  8   AIR  8  on Q4 result  MTG  8   ARQL  8  on pricing of common stock  RXII  8   TKC  7   STAF  6   IDRA  6  as merger terminated  SOGO  5   FUN  5  on reporting revenue  TS  5   Now read ,2018-07-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-07102018-1525503,1525503
4215,225730,ARQL,After Hours Gainers   Losers  07 10 2018 ,news,Top gainers OCX  53 5   VSAR  9 7  OTC LNNFF  3 7   SESN  2 5   TVIX  2 1   Top Losers VOXX  13 5   ARQL  8 0    AIR  2 8   OTCQB AXIM  2 5   JWN  1 8   Now read ,2018-07-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/after-hours-gainers--losers-07102018-1524566,1524566
4218,225733,ARQL,Key events next week   healthcare,news,"Noteworthy events during the week of November 25   December 1 for healthcare investors  
MONDAY  11 26   FDA action date for Loxo Oncology s  NASDAQ LOXO  larotrectinib in NTRK fusion positive solid tumors  
Genocea Biosciences  NASDAQ GNCA   KOL event on personalized cancer immunotherapies  NYC  
WEDNESDAY  11 28   FDA action date for  Catalyst Pharmaceuticals    NASDAQ CPRX  Firdapse for LEMS and Astellas Pharma s  OTCPK ALPMF  gilteritinib for FLT3 positive AML  
THURSDAY  11 29   American Epilepsy Society Annual Meeting  New Orleans  6 days   Marinus Pharmaceuticals  NASDAQ MRNS   Data on ganaxolone in children with CDKL5 Deficiency Disorder and PCDH19 related epilepsy  GW Pharmaceuticals  NASDAQ GWPH   Phase 3 Epiolex data  preclinical and Phase 1 cannabidiol data  
SATURDAY  12 1   American Society of Hematology  ASH  Annual Meeting  San Diego  4 days    Argenx   NASDAQ ARGX   Phase 2 data on efgartimod in primary immune thrombocytopenia  TG Therapeutics  NASDAQ TGTX   Updated data on U2  Sierra Oncology  NASDAQ SRRA   Momelotinib data   Sunesis Pharmaceuticals   NASDAQ SNSS   Vecabrutinib data  Atara Biotherapeutics  NASDAQ ATRA   Off the shelf CAR T therapies  MiRagen Therapeutics  NASDAQ MGEN   Phase 1 data on cobomarsen  Bio Path Holdings  NASDAQ BPTH   Phase 2 data on BP1001  prexigebersen   Acceleron Pharma  NASDAQ XLRN   Phase 3 data on luspatercept in MDS and beta thalassemia  Affimed  NASDAQ AFMD   Six abstracts  Verastem Oncology  NASDAQ VSTM   Eight abstracts  Daiichi Sankyo  OTCPK DSKYF   Phase 1 data on valemetostat  Phase 3 data on quizartinib preclinical data in quizartinib   milademetan  Bluebird bio  NASDAQ BLUE   Phase 3 data on lentiglobin in beta thalassemia  Phase 1 data on lentiglobin in SCD  Phase 1 data on bb21217 in MM  Phase 1 data on BCL11a shRNAmiR in SCD  Allogene Therapeutics  NASDAQ ALLO   Pipeline data  Global Blood Therapeutics  NASDAQ GBT   Four abstracts in SCD  including voxelotor  Unum Therapeutics  NASDAQ UMRX   Phase 1 data on ACTR707  with rituximab  in CD20  B cell lymphomas  Celgene  NASDAQ CELG   More than 100 abstracts  GlycoMimetics  NASDAQ GLYC   Phase 1 2 data on uproliselan   chemo in AML   NewLink Genetics   NASDAQ NLNK   Phase 1 data on indoximod in AML  Xencor  NASDAQ XNCR   Phase 1 data on XmAb 14045 in AML   ImmunoGen   NASDAQ IMGN   IMGN779 and IMGN632 data  Celyad  NASDAQ CYAD   Phase 1 data on CYAD 01 in AML  Fate Therapeutics  NASDAQ FATE   Preclinical data on FT500  Phase 1 data on ProTmune  introduce FATE NK100  Bellicum Pharmaceuticals  NASDAQ BLCM   Eight abstracts on lead candidate rivo cel  BPX 501    Magenta Therapeutics   NASDAQ MGTA   Five abstracts on ADCs  Phase 2 data on MGTA 456  Actinium Pharmaceuticals  NYSEMKT ATNM   Multiple abstracts on antibody radiation conjugates  Phase 3 data on Iomab B  Roche  OTCQX RHHBY   Over 70 abstracts  Stemline Therapeutics  NASDAQ STML   Four abstracts on Elzonris  tagraxofusp  SL 401   Humanigen  OTCQB HGEN   Preclinical data on lenzilumab   CART19 for preventing CRS  Novartis  NYSE NVS   Multiple abstracts  update on Kymriah in DLBCL  Seattle Genetics  NASDAQ SGEN   Phase 3 data on Adcetris in first line CD30  peripheral T cell lymphoma  MorphoSys  NASDAQ MOR   Phase 2 data on MOR208 and Phase 1 2a data on MOR202   ArQule   NASDAQ ARQL   Phase 1 data on ARQ 531  Now read ",2018-11-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/key-events-next-week--healthcare-1698889,1698889
4219,225734,ARQL,U S  stocks lower at close of trade  Dow Jones Industrial Average down 0 07 ,news,"Investing com   U S  stocks were lower after the close on Friday  as losses in the Oil   Gas  Technology and Basic Materials sectors led shares lower 
At the close in NYSE  the Dow Jones Industrial Average lost 0 07   while the S P 500 index lost 0 16   and the NASDAQ Composite index declined 0 52  
The best performers of the session on the Dow Jones Industrial Average were  Home Depot  Inc  NYSE HD   which rose 1 71  or 3 47 points to trade at 205 82 at the close  Meanwhile   Verizon Communications  Inc  NYSE VZ  added 1 16  or 0 67 points to end at 58 29 and UnitedHealth Group Incorporated  NYSE UNH  was up 0 62  or 1 51 points to 245 39 in late trade 
The worst performers of the session were Dow Inc  NYSE DOW   which fell 3 29  or 1 74 points to trade at 51 14 at the close  Cisco Systems Inc  NASDAQ CSCO  declined 2 53  or 1 42 points to end at 54 75 and 3M Company  NYSE MMM  was down 1 30  or 2 19 points to 166 66 
The top performers on the S P 500 were  Facebook Inc   NASDAQ FB  which rose 2 17  to 181 33   Ventas Inc   NYSE VTR  which was up 2 03  to settle at 66 76 and CF Industries Holdings Inc  NYSE CF  which gained 1 91  to close at 46 00 
The worst performers were Signet Jewelers Ltd  NYSE SIG  which was down 5 96  to 17 98 in late trade   F5 Networks Inc   NASDAQ FFIV  which lost 5 65  to settle at 136 93 and Broadcom Inc  NASDAQ AVGO  which was down 5 57  to 265 93 at the close 
The top performers on the NASDAQ Composite were SSLJ com Ltd  NASDAQ YGTY  which rose 32 80  to 3 3200   ArQule  Inc  NASDAQ ARQL  which was up 30 37  to settle at 8 200 and Puyi Inc ADR  NASDAQ PUYI  which gained 26 07  to close at 7 98 
The worst performers were Sellas Life Sciences Group Inc  NASDAQ SLS  which was down 57 49  to 0 1600 in late trade  Novus Therapeutics Inc  NASDAQ NVUS  which lost 19 85  to settle at 1 0500 and  Seres Therapeutics Inc   NASDAQ MCRB  which was down 19 43  to 2 28 at the close 
Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1813 to 1180 and 32 ended unchanged  on the Nasdaq Stock Exchange  1695 fell and 967 advanced  while 81 ended unchanged 
Shares in Signet Jewelers Ltd  NYSE SIG  fell to 5 year lows  down 5 96  or 1 14 to 17 98  Shares in Ventas Inc  NYSE VTR  rose to 52 week highs  gaining 2 03  or 1 33 to 66 76  Shares in Sellas Life Sciences Group Inc  NASDAQ SLS  fell to all time lows  down 57 49  or 0 2164 to 0 1600  Shares in ArQule Inc  NASDAQ ARQL  rose to 5 year highs  up 30 37  or 1 910 to 8 200  Shares in Novus Therapeutics Inc  NASDAQ NVUS  fell to all time lows  down 19 85  or 0 2600 to 1 0500  Shares in Puyi Inc ADR  NASDAQ PUYI  rose to all time highs  rising 26 07  or 1 65 to 7 98  Shares in Seres Therapeutics Inc  NASDAQ MCRB  fell to all time lows  losing 19 43  or 0 55 to 2 28  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 3 41  to 15 28 
Gold Futures for August delivery was up 0 12  or 1 65 to  1345 35 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 0 46  or 0 24 to hit  52 52 a barrel  while the August Brent oil contract rose 1 21  or 0 74 to trade at  62 05 a barrel 
EUR USD was down 0 59  to 1 1209  while USD JPY rose 0 17  to 108 56 
The US Dollar Index Futures was up 0 56  at 97 540 ",2019-06-14,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-lower-at-close-of-trade-dow-jones-industrial-average-down-007-1898453,1898453
4220,225735,ARQL,ArQule up 101  premarket on Merck bid,news,"Merck  NYSE MRK  has agreed to acquire ArQule  NASDAQ ARQL  for  20 per share in cash  valuing the transaction at  2 7B 
ArQule s lead candidate is ARQ 531  an oral BTK inhibitor in Phase 2 development for B cell malignancies 
Shares up 101  premarket on robust volume 
Update  ARQL will host an investor event this morning starting at 8 00 am ET to discuss ARQ 531 data being presented at ASH  A conference call and webcast will start at 8 15 am ET  The ASH presentation of Phase 1 results is scheduled for today at 6 00 pm ET ",2019-12-09,Seeking Alpha,https://invst.ly/o-4v9,2036760
4230,225745,ARQL,50 Cash Rich Biotech Stocks Being Snapped Up By Hedge Funds,opinion,Screen Criteria  List of Biotech stocks that also have significant cash holdings  when compared to quarterly operating expenses  Average Weekly Returns  Average 1 Week Return of All Stocks Mentioned Below  3 18  Average 1 Month Return of All Stocks Mentioned Below  7 17  Analysis of List Alpha  Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Week   34 out of 50  68 0   Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Month   29 out of 50  58 0   Chart  Distribution of 1 Week Returns For All Stocks Mentioned Below Chart  Distribution of 1 Month Returns For All Stocks Mentioned Below1  Infinity Pharmaceuticals  Inc   INFI   Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States  Average quarterly operating expense over the last five quarters at  24 72M  vs  most recent cash and short term investments at  188 77M  implies a Cash   Avg  Operating Expense ratio at 7 64    2  Sequenom Inc   SQNM   Provides products  services  diagnostic testing  applications  and genetic analysis products that translate the results of genomic science into solutions for biomedical research  translational research  molecular medicine applications  and agricultural and livestock research  Average quarterly operating expense over the last five quarters at  41 71M  vs  most recent cash and short term investments at  193 39M  implies a Cash   Avg  Operating Expense ratio at 4 64    3  BioSante Pharmaceuticals  Inc   BPAX   Develops products for female sexual health and oncology  Average quarterly operating expense over the last five quarters at  8 77M  vs  most recent cash and short term investments at  38 05M  implies a Cash   Avg  Operating Expense ratio at 4 34    4  Amicus Therapeutics  Inc   FOLD   Focuses on the discovery  development  and commercialization of orally administered  small molecule drugs for the treatment of various human genetic diseases  Average quarterly operating expense over the last five quarters at  18 6M  vs  most recent cash and short term investments at  106 22M  implies a Cash   Avg  Operating Expense ratio at 5 71    5  Corcept Therapeutics Incorporated  CORT   Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders  Average quarterly operating expense over the last five quarters at  8 92M  vs  most recent cash and short term investments at  101 63M  implies a Cash   Avg  Operating Expense ratio at 11 39    6  Medivation  Inc   MDVN   Focuses on the development of small molecule drugs for the treatment of castration resistant prostate cancer  Alzheimer s disease  and Huntington disease  Average quarterly operating expense over the last five quarters at  39 47M  vs  most recent cash and short term investments at  340 41M  implies a Cash   Avg  Operating Expense ratio at 8 62    7  Alnylam Pharmaceuticals  Inc   ALNY   Focuses on the discovery  development  and commercialization of novel therapeutics based on RNA interference  RNAi   Average quarterly operating expense over the last five quarters at  33 32M  vs  most recent cash and short term investments at  228 34M  implies a Cash   Avg  Operating Expense ratio at 6 85    8  Sangamo Biosciences Inc   SGMO   Engages in the research  development  and commercialization of zinc finger DNA binding proteins  ZFPs  for gene regulation and gene modification in the United States  Average quarterly operating expense over the last five quarters at  10 82M  vs  most recent cash and short term investments at  57 9M  implies a Cash   Avg  Operating Expense ratio at 5 35    9  Transcept Pharmaceuticals  Inc   TSPT   Average quarterly operating expense over the last five quarters at  5 87M  vs  most recent cash and short term investments at  98 67M  implies a Cash   Avg  Operating Expense ratio at 16 81    10  ArQule Inc   ARQL   Engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes  Average quarterly operating expense over the last five quarters at  12 85M  vs  most recent cash and short term investments at  82 76M  implies a Cash   Avg  Operating Expense ratio at 6 44    11  Ariad Pharmaceuticals Inc   ARIA   Focuses on the discovery  development  and commercialization of small molecule drugs for the treatment of cancer  Average quarterly operating expense over the last five quarters at  40 56M  vs  most recent cash and short term investments at  206 66M  implies a Cash   Avg  Operating Expense ratio at 5 1    12  Cytokinetics  Incorporated  CYTK   Engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions  Average quarterly operating expense over the last five quarters at  11 82M  vs  most recent cash and short term investments at  75 61M  implies a Cash   Avg  Operating Expense ratio at 6 4    13  Halozyme Therapeutics  Inc   HALO   Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits  Average quarterly operating expense over the last five quarters at  21 68M  vs  most recent cash and short term investments at  87 61M  implies a Cash   Avg  Operating Expense ratio at 4 04    14  Xenoport  Inc   XNPT   Focuses on developing and commercializing internally discovered product candidates that utilize the body s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs  Average quarterly operating expense over the last five quarters at  19 34M  vs  most recent cash and short term investments at  112 86M  implies a Cash   Avg  Operating Expense ratio at 5 83    15  Immunogen Inc   IMGN   Engages in the research and development of antibody based anticancer therapeutics in the United States  Average quarterly operating expense over the last five quarters at  23 79M  vs  most recent cash and short term investments at  233 61M  implies a Cash   Avg  Operating Expense ratio at 9 82    16  Illumina Inc   ILMN   Develops  manufactures  and markets integrated systems for the analysis of genetic variation and biological function  Average quarterly operating expense over the last five quarters at  223 87M  vs  most recent cash and short term investments at  1233 07M  implies a Cash   Avg  Operating Expense ratio at 5 51    17  Osiris Therapeutics  Inc   OSIR   Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory  autoimmune  orthopedic  and cardiovascular areas  Average quarterly operating expense over the last five quarters at  5 97M  vs  most recent cash and short term investments at  37 22M  implies a Cash   Avg  Operating Expense ratio at 6 24    18  Onyx Pharmaceuticals  Inc   ONXX   Engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally  Average quarterly operating expense over the last five quarters at  116 42M  vs  most recent cash and short term investments at  554 79M  implies a Cash   Avg  Operating Expense ratio at 4 77    19  Exact Sciences Corporation  EXAS   Focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre cancer and cancer  Average quarterly operating expense over the last five quarters at  12 31M  vs  most recent cash and short term investments at  118 57M  implies a Cash   Avg  Operating Expense ratio at 9 63    20  Pain Therapeutics Inc   PTIE   Engages in the research and development of novel drugs  Average quarterly operating expense over the last five quarters at  3 52M  vs  most recent cash and short term investments at  92 53M  implies a Cash   Avg  Operating Expense ratio at 26 32    21  Idenix Pharmaceuticals Inc   IDIX   Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe  Average quarterly operating expense over the last five quarters at  22 45M  vs  most recent cash and short term investments at  251 87M  implies a Cash   Avg  Operating Expense ratio at 11 22    22  Targacept  Inc   TRGT   Engages in the design  discovery  and development of novel Neuronal Nicotinic Receptors  NNR  Therapeutics for the treatment of diseases and disorders of the central nervous system  Average quarterly operating expense over the last five quarters at  21 31M  vs  most recent cash and short term investments at  195 61M  implies a Cash   Avg  Operating Expense ratio at 9 18    23  Geron Corporation  GERN   Develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases  including spinal cord injury  heart failure  and diabetes  Average quarterly operating expense over the last five quarters at  21 55M  vs  most recent cash and short term investments at  100 45M  implies a Cash   Avg  Operating Expense ratio at 4 66    24  Celgene Corporation  CELG   Develops  and commercializes various therapies to treat cancer and immune inflammatory related diseases  Average quarterly operating expense over the last five quarters at  866 38M  vs  most recent cash and short term investments at  3832 94M  implies a Cash   Avg  Operating Expense ratio at 4 42    25  Repros Therapeutics Inc   RPRX   Average quarterly operating expense over the last five quarters at  3 36M  vs  most recent cash and short term investments at  29 58M  implies a Cash   Avg  Operating Expense ratio at 8 8    26  Enzon Pharmaceuticals Inc   ENZN   Engages in the research and development of therapeutics for cancer patients with unmet medical needs  Average quarterly operating expense over the last five quarters at  11 98M  vs  most recent cash and short term investments at  278 44M  implies a Cash   Avg  Operating Expense ratio at 23 23    27  InterMune Inc   ITMN   Focuses on developing and commercializing therapies in pulmonology and hepatology  Average quarterly operating expense over the last five quarters at  49 48M  vs  most recent cash and short term investments at  351 4M  implies a Cash   Avg  Operating Expense ratio at 7 1    28  OncoGenex Pharmaceuticals  Inc   OGXI   Engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients  Average quarterly operating expense over the last five quarters at  8 91M  vs  most recent cash and short term investments at  85 07M  implies a Cash   Avg  Operating Expense ratio at 9 55    29  Amgen Inc   AMGN   Develops  manufactures  and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States  Europe  and Canada  Average quarterly operating expense over the last five quarters at  2917M  vs  most recent cash and short term investments at  25374M  implies a Cash   Avg  Operating Expense ratio at 8 7    30  Seattle Genetics Inc   SGEN   Focuses on the development and commercialization of monoclonal antibody based therapies for the treatment of cancer and autoimmune diseases in the United States  Average quarterly operating expense over the last five quarters at  64 52M  vs  most recent cash and short term investments at  313 93M  implies a Cash   Avg  Operating Expense ratio at 4 87    31  Alexion Pharmaceuticals  Inc   ALXN   Engages in the discovery  development  and commercialization of biologic therapeutic products in the United States  Europe  Latin America  Japan  and the Asia Pacific  Average quarterly operating expense over the last five quarters at  161 43M  vs  most recent cash and short term investments at  905 53M  implies a Cash   Avg  Operating Expense ratio at 5 61    32  VIVUS Inc   VVUS   Engages in the development and commercialization of therapeutic products for underserved markets in the United States  Average quarterly operating expense over the last five quarters at  20 9M  vs  most recent cash and short term investments at  274 48M  implies a Cash   Avg  Operating Expense ratio at 13 13    33  Arena Pharmaceuticals  Inc   ARNA   Focuses on discovering  developing  and commercializing oral drugs in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Average quarterly operating expense over the last five quarters at  22 4M  vs  most recent cash and short term investments at  165 77M  implies a Cash   Avg  Operating Expense ratio at 7 4    34  Curis Inc   CRIS   Focuses on the research and development of cancer therapeutics  Average quarterly operating expense over the last five quarters at  6 39M  vs  most recent cash and short term investments at  41 14M  implies a Cash   Avg  Operating Expense ratio at 6 44    35  Sunesis Pharmaceuticals Inc   SNSS   Focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers  Average quarterly operating expense over the last five quarters at  9 03M  vs  most recent cash and short term investments at  76 55M  implies a Cash   Avg  Operating Expense ratio at 8 48    36  Oncothyreon Inc  ONTY   Focuses on the development of therapeutic products for the treatment of cancer  Average quarterly operating expense over the last five quarters at  6 96M  vs  most recent cash and short term investments at  79 16M  implies a Cash   Avg  Operating Expense ratio at 11 37    37  Threshold Pharmaceuticals Inc   THLD   Engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer  Average quarterly operating expense over the last five quarters at  6 76M  vs  most recent cash and short term investments at  65 83M  implies a Cash   Avg  Operating Expense ratio at 9 74    38  Lexicon Pharmaceuticals  Inc   LXRX   Focuses on the discovery and development of drug candidates for the treatment of various human diseases  Average quarterly operating expense over the last five quarters at  28 91M  vs  most recent cash and short term investments at  206 42M  implies a Cash   Avg  Operating Expense ratio at 7 14    39  Achillion Pharmaceuticals  Inc   ACHN   Engages in the discovery  development  and commercialization of treatments for infectious diseases  Average quarterly operating expense over the last five quarters at  12 32M  vs  most recent cash and short term investments at  80 91M  implies a Cash   Avg  Operating Expense ratio at 6 57    40  PDL BioPharma  Inc   PDLI   Engages in the management of antibody humanization patents and royalty assets  which consist of Queen et al  Average quarterly operating expense over the last five quarters at  5 3M  vs  most recent cash and short term investments at  160 37M  implies a Cash   Avg  Operating Expense ratio at 30 24    41  Nektar Therapeutics  NKTR   Engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms  Average quarterly operating expense over the last five quarters at  51 3M  vs  most recent cash and short term investments at  319 28M  implies a Cash   Avg  Operating Expense ratio at 6 22    42  Vical Inc   VICL   Engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid  DNA  delivery technologies for the prevention and treatment of serious or life threatening diseases  Average quarterly operating expense over the last five quarters at  10 05M  vs  most recent cash and short term investments at  86 89M  implies a Cash   Avg  Operating Expense ratio at 8 64    43  Exelixis  Inc   EXEL   Engages in the discovery  development  and commercialization of small molecule drugs for the treatment of cancer  metabolic  and cardiovascular disorders  Average quarterly operating expense over the last five quarters at  42 08M  vs  most recent cash and short term investments at  484 59M  implies a Cash   Avg  Operating Expense ratio at 11 52    44  Vanda Pharmaceuticals  Inc   VNDA   Focuses on the development and commercialization of products for the treatment of central nervous system disorders  Average quarterly operating expense over the last five quarters at  14 43M  vs  most recent cash and short term investments at  134 4M  implies a Cash   Avg  Operating Expense ratio at 9 32    45  Agenus Inc   AGEN   Develops and commercializes immunotherapies for cancer and infectious diseases  Average quarterly operating expense over the last five quarters at  5 61M  vs  most recent cash and short term investments at  25 46M  implies a Cash   Avg  Operating Expense ratio at 4 54    46  AVEO Pharmaceuticals  Inc   AVEO   Engages in the discovery and development of cancer therapeutics  Average quarterly operating expense over the last five quarters at  29 4M  vs  most recent cash and short term investments at  189 69M  implies a Cash   Avg  Operating Expense ratio at 6 45    47  Insmed Incorporated  INSM   Focuses on the development of inhaled pharmaceuticals for the site specific treatment of serious lung diseases  Average quarterly operating expense over the last five quarters at  14 45M  vs  most recent cash and short term investments at  89 75M  implies a Cash   Avg  Operating Expense ratio at 6 21    48  Momenta Pharmaceuticals Inc   MNTA   Momenta Pharmaceuticals  Inc   a biotechnology company  specializes in the in the characterization and process engineering of complex molecules  Average quarterly operating expense over the last five quarters at  30 37M  vs  most recent cash and short term investments at  361 82M  implies a Cash   Avg  Operating Expense ratio at 11 91    49  BioSpecifics Technologies Corp   BSTC   Involves in the development of an injectable collagenase for various indications  Average quarterly operating expense over the last five quarters at  1 47M  vs  most recent cash and short term investments at  9 01M  implies a Cash   Avg  Operating Expense ratio at 6 13    50  ZIOPHARM Oncology  Inc   ZIOP   Focuses on the development and commercialization of in licensed cancer drugs in North America  Average quarterly operating expense over the last five quarters at  18 99M  vs  most recent cash and short term investments at  95 33M  implies a Cash   Avg  Operating Expense ratio at 5 02 ,2012-12-14,Contextuall,https://www.investing.com/analysis/50-cash-rich-biotech-stocks-being-snapped-up-by-hedge-funds-147579,147579
4231,225746,ARQL,ArQule  A Strong Speculation Bio Pharma Poised,opinion,ArQule  ARQL  engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes  Its lead product candidate Tivantinib  ARQ 197  is an inhibitor of the c Met receptor tyrosine kinase  which is in Phase 3 clinical trial for the treatment of liver cancer and colorectal cancer  CRC   The company also develops ARQ 621  an inhibitor of the Eg5 kinesin motor protein that has completed Phase I trial  ARQ 736  an inhibitor of the RAF kinases  which is in Phase I clinical trial  ARQ 761  an activator of the E2F 1 damage response checkpoint pathway  and ARQ 087  an inhibitor of fibroblast growth factor receptor that is in pre clinical stage  It has partnership agreement with Daiichi Sankyo Co   Ltd  and Kyowa Hakko Kirin Co   Ltd  The lead product candidate is Tivantinib  ARQ 197   an orally administered  small molecule inhibitor of the c Met receptor tyrosine kinase  C Met is a promising target for cancer therapy based on its multiple roles in cancerous cell proliferation  tumor spread  new blood vessel formation and resistance to certain drug therapies  Arqule and its partners  Daiichi Sankyo Co   Ltd  and Kyowa Hakko Kirin Co   Ltd  are implementing a clinical development program designed to realize the broad potential of Tivantinib as a well tolerated single agent and in combination with other anti cancer therapies in a number of disease indications The company s strategy is to focus on the most promising indications within the clinical programs based upon data that is continually generated  Its leading indications include liver cancer  non small cell lung cancer  and colorectal cancer  The company is also completing earlier stage combination therapy trials with Tivantinib and other anti cancer agents that may provide data to support later stage trials in additional indications  On October 16  2012  the company announced a Special Protocol Assessment agreement with the U S  Food and Drug Administration for the design of a pivotal Phase III trial of Tivantinib in patients with HCC  The Phase III trial will be a randomized  double blinded study of Tivantinib as single agent therapy in previously treated patients with MET diagnostic high inoperable HCC  The primary endpoint is overall survival in the intent to treat population  and the secondary endpoint is progression free survival in the same population  Approximately 300 patients are planned to be enrolled at approximately 120 centers worldwide  ArQule has advanced into Phase III clinical with ARQ 197  C Met is a promising target for cancer therapy  as evidence suggests that it plays multiple roles in cancerous cell proliferation  tumor spread  new blood vessel formation and drug resistance  The company believes that the inappropriate expression of c Met in many cancers and its involvement in multiple signal transduction pathways affecting tumor growth and metastasis render it a compelling target for cancer therapy  Oncology research and development activities are increasingly focused on kinases  which play pivotal roles in modulating diverse cellular activities and have been implicated as important mediators of certain forms of cancer and other diseases  The success of kinase inhibitors such as Gleevec and Nexavar has focused attention on the kinase field  resulting in the increased development of next generation inhibitors that target cancers and other diseases such as inflammation  The current market for protein kinase inhibitors is estimated to exceed  7 billion  and by 2020  small molecule kinase inhibitors are projected to generate collectively annual revenues greater than  25 billion    ArQule has extensively studied the mechanism by which ARQ 197 selectively inhibits its target c Met receptor kinase  These studies have revealed the molecular and structural basis by which ARQ 197 targets c Met  ARQ 197 inhibits c Met autophosphorylation and is selective for the inactive or unphosphorylated form of c Met  Elucidation of this novel mode of inhibition of c Met has opened up the opportunity for the design and development of similar selective inhibitors for other kinases  Drug discovery at ArQule utilizes a proven innovative and efficient drug discovery engine which employs a proprietary structure based drug design technology known as the ArQule Kinase Inhibitor Platform AKIP    This platform targets inactive forms of kinases that have pivotal roles in cancer and other diseases  AKIP integrates in silico drug design  parallel robotic chemistry  and novel assay development expertise to create non ATP competitive inhibitors that interact with these kinases in novel binding modes  Inhibitors identified through AKIP are optimized into drug candidates having the appropriate efficacy and selectivity for their target with minimal side effects   The company believes it has within this platform the capability to rationally design novel kinase inhibitors that encompass new chemical spaces and allow for an expanding intellectual property estate  It anticipates that these novel kinase inhibitors  when targeted against selected therapeutically relevant kinases  will have utility in a broad range of human diseases in addition to cancer  The company is seeking to expand the applications of this proprietary drug discovery platform through collaborative research programs as well as through our own internal discovery and development activities in multiple therapeutic areas   ArQule has a collaboration with Daiichi Sankyo Co   Ltd  to apply its AKIP technology in the discovery of therapeutic compounds that selectively inhibit certain kinases in the field of oncology  It is also independently applying AKIP to the discovery of inhibitors of fibroblast growth factor receptor  FGFR   Progress to date has resulted in a series of small molecule inhibitors of FGFR that are not ATP competitive and show potent anti tumor activity in FGFR driven human and animal cancer models  Daiichi Sankyo  DS  is ArQule s co development worldwide partner for ARQ 197   except Asia  and paid ArQule  60 Mil upfront  with another  560M due for potential milestones and tiered double digit royalties  The most recent milestone was a  25M payment for the initiation of the MARQUEE Phase III trial  DS retains all ex Asia commercial rights  with ArQule retaining the US co commercialization rights  There has been some speculation that DS is considering acquiring ArQule  but I have yet to hear from a real source on this front regarding this  Right off the bat  it seems to me that ArQule is very undervalued speculation wise  with its current market cap of  178 30M  Right off the bat  it seems to me that ArQule is very undervalued speculation wise  with its current market cap of  178 30M  Daiichi Sankyo  DS  is ArQule s co development worldwide partner for ARQ 197   except Asia  and paid ArQule  60 Mil upfront  with another  560M due for potential milestones and tiered double digit royalties  The most recent milestone was a  25M payment for the initiation of the MARQUEE Phase III trial  DS retains all ex Asia commercial rights  with ArQule retaining the US co commercialization rights  Potential catalyst trade  Phase II top line data covering CRC is due out by the end of this year early next year for ARQ 197  The data release will estimate the difference in progression free survival  PFS  between the study and control arms in subjects with CRC with wild type KRAS who have received front line therapy  Positive data here would likely gap the stock up considerably  so traders should keep an eye out for this  Wi an Eg5 Inhibitor  a BRAF Inhibitor  an FGFR Inhibitor  and an AKT Inhibitor   a deep pipeline along with the near term catalyst event of top line Phase II data  makes the company s  178 30M market cap undervalued for a mid stage Oncology biotech in my opinion  and also makes for a good catalyst trade opportunity   Institutions have increased their stake by over 10  in the company lately  which is always a good sign  The above chart was taken from Robert Pedone s  published a couple of weeks ago  I spoke to Robert yesterday to get his updated take on the charts  and we both agree that if the stock breaks past  3 on decent volume  we could see an upwards gap fill to  4 rather quickly  With the data release expected any day now  I feel ArQule is a good long side trade for the short term  and with good data  possibly a longer term buy and hold  The Biopharma segment of the market is rather hot these days with companies like Sarepta  SRPT  and Acadia  ACAD  recently seeing large price gaps up on positive data releases  My short term price target opinion is  4 a share  and a 1 year target over  10 if the company s platform proves successful in 2013 ,2012-12-18,Scott Matusow,https://www.investing.com/analysis/arqule:-a-strong-speculation-bio-pharma-poised-148078,148078
4232,225747,ARQL,ArQule Update On HCC mCRC Trials  Study Misses  Trial Starts ,opinion,CRC study misses  HCC trial startsThe failure of ArQule s  ARQL  tivantinib to show a statistically significant increase in PFS in a Phase II trial in second line metastatic colorectal cancer  mCRC  makes further development in this disease setting a challenging prospect for ArQule and its partners  Meanwhile  the Phase III trial in second line hepatocellular carcinoma  HCC  is now underway  with the first clinical sites now open for patient enrolment  Despite its recent clinical study misfortunes  ArQule remains on solid financial ground  with an estimated  130m of cash and cash equivalents at the end of 2012  sufficient to support operations into 2015  when final data of the Phase III HCC trial should become available mCRC misses primary end pointThe Phase II trial in second line mCRC of tivantinib in combination with irinotecan Erbitux showed a numerically superior median PFS  8 3 months  than control  irinotecan Erbitux  7 3 months   but this did not reach statistical significance  p 0 65   There was an encouraging trend of response rate  45  vs 33    overall survival  OS  data are immature  but these are unlikely to be positive  ArQule and its partner Daiichi Sankyo intend to analyse subgroup data  such as in high c Met patients  50  of the enrolled patients  or about 60  have c Met measured in the trial  and report those findings at a future meeting  However  in the light of these data  further development for tivantinib for mCRC is unlikely to be an attractive option given the evolving competitive landscape  in our opinion HCC Phase III trial underwayNevertheless  the Phase III trial  to be called METIV  was listed on Clinicaltrials gov on 19 December and at least one site is now open for patient enrolment  The listing confirms the previously communicated design with 303 patients with second line  high c Met inoperable HCC to be recruited with the primary endpoint of OS in intent to treat  ITT  population  The trial is expected to be complete by December 2015  similar to our previous estimate  making approval possible in 2016 Valuation   324m without value from mCRCWe have revised our valuation in the light of the mCRC study result  and now value ArQule at  324m or  4 65 per share  fully diluted   based on our risk adjusted DCF model  This includes tivantinib rNPV at  169m  without contribution from mCRC  which we previously valued at  52m   25m for other assets and estimated year end net cash of  130m  Nevertheless  our value of ArQule is significantly higher than its market cap  suggesting potential for share appreciation To Read the Entire Report Please Click on the pdf File Below ,2013-01-15,Edison,"https://www.investing.com/analysis/arqule-update-on-hcc-mcrc-trials:-study-misses,-trial-starts-151008",151008
4233,225748,ARQL,ArQule  Post Q4 Results Update ,opinion,2013 will be a transitional year2013 will be a year in which ArQule   ARQL   and its partners are focused on progressing and or completing clinical trials with tivantinib  but one which sees relatively few new clinical data read outs  The speed of patient accrual in the recently opened METIV Phase III trial in hepatocellular carcinoma will  however  be an important signal  ArQule s current up to 30 months target for recruitment could be very conservative  This will determine the timing of the interim analysis  which could come as early as late 2014  The start of a Phase I trial of ARQ 087 brings a new compound into clinical trials  while the future of ARQ 621 and ARQ 736 should soon be decided HCC Phase III trial underwayArQule has now dosed the first patients in the METIV Phase III trial in HCC and aims to complete patient enrolment in two and half years  ie mid 2015  a timeline the management characterises as conservative  The trial has built in an efficacy and safety interim analysis  which could be potentially triggered in late 2014 if accrual and events accumulate fast  However  given announcements of several new Phase III trials in second line HCC by competitors  ArQule may face more competition for patients  Nevertheless  we continue to expect tivantinib to reach the market in 2016 Pipeline shuffleArQule has started a Phase I trial of ARQ 087  an orally bioavailable  multi kinase inhibitor with pan FGFR  fibroblast growth factor receptor  activity  At the same time  two other pipeline compounds  ARQ 621  an Eg5 inhibitor  and ARQ 736  a BRAF inhibitor  may be discontinued from development  pending final Phase I data and competitive landscape analysis  In addition  ArQule is conducting a Phase I study of ARQ 092  an AKT inhibitor for Daiichi Sankyo  which holds worldwide rights arising from a kinase inhibitor collaboration that ended in 2012 Valuation   300m or  4 30 per diluted shareWe have revised our valuation to reflect a rebasing of the NPV to 2013 and to the company s guided cash utilisation this year  We now value ArQule at  300m or  4 30 per share  fully diluted   vs our previous  4 65 share figure  based on our risk adjusted DCF model  This includes tivantinib rNPV at  190m vs previously  165m   25m for other assets and estimated 2013 year end net cash of  85m  Our valuation for ArQule is significantly higher than its current market capitalisation  highlighting the potential for share price appreciation To Read the Entire Report Please Click on the pdf File Below ,2013-03-19,Edison,https://www.investing.com/analysis/arqule:-post-q4-results-update-159604,159604
4234,225749,ARQL,ArQule Inc   276m Or  4 48 Per Diluted Share ,opinion,"Value of c Met inhibitor in NSCLC questioned
Detailed data presented at ASCO 2014 on c Met inhibitors  including Roche s onartuzumab and ArQule Inc s  NASDAQ ARQL  tivantinib  failed to show much clinical benefit when a c Met inhibitor is added to other therapies in NSCLC  and posed the question of whether inhibiting c Met in this disease setting is clinically meaningful  This  however  should not have reduced tivantinib s value in HCC  in which two Phase III trials  METIV HCC and JET HCC  are progressing in second line HCC  ArQule ended Q114 with cash and marketable securities of  85 8m  enough to support its operation beyond 2015 

Met inhibition in NSCLC failed to show efficacy
Detailed data of the Phase III METLung trial  stopped prematurely in March 2014 after it failed a pre planned interim futility analysis  showed that the combination of onartuzumab  an anti Met mAb  and Tarceva  Roche  did not have any clinical benefit  OS  PFS and ORR  over placebo and Tarceva in NSCLC patients with high c Met expression status  This was in contrast to OS and PFS benefits seen in the same patient population in a previous Phase II trial  Similarly  the combination of tivantinib and Tarceva  t T  failed to show any clinical benefit over placebo and Tarceva in previously treated  squamous NSCLC with EGFR wild type  c Met high patients  The t T combination did cause higher incidences of interstitial lung disease  ILD   which caused the ATTENTION trial to be stopped prematurely in August 2012  The lack of clinical benefit of a c Met inhibitor when added to an EGFR inhibitor  Tarceva is an EGFR inhibitor  in patients with high c Met expression  patients were specifically selected based on their high c Met status in both trials  has casted doubts on c Met as a valid drug target in NSCLC 
No crossover read to tivantinib in HCC
We continue to caution a crossover read of the NSCLC results into that of HCC  and  more specifically  the probability of success of tivantinib in the ongoing Phase III METIV HCC  The trial was based on a positive Phase II trial in which a statistically significant OS benefit was demonstrated  and tivantinib was compared to a placebo  a lower hurdle than Tarceva  in the two aforementioned trials 
Valuation   276m or  4 48 per diluted share
We value the company at  276m  a slight decrease from our previous  283m  based on slightly lower end 2014 cash  Our pipeline value remains at  217m  including  192m from tivantinib in second line  c Met high HCC and  25m for ARQ 087 and 092  both are in Phase I trials for solid tumours 
To Read the Entire Report Please Click on the pdf File Below",2014-06-15,Edison,https://www.investing.com/analysis/arqule-inc:-$276m-or-$4.48-per-diluted-share-216070,216070
4235,225750,ARQL,Keryx  KERX  Q1 Loss In Line  Auryxia Up On Strong Demand  Revised ,opinion,"Keryx Biopharmaceuticals Inc  s   NASDAQ KERX   first quarter 2016 loss of 22 cents per share  excluding  15 7 million in non cash interest expense related to amortization of the debt discount on its convertible senior notes and a  2 0 million non cash charge related to the increase in fair value of derivative liability that was recorded in connection with the issuance of convertible senior notes  was in line with the Zacks Consensus Estimate but wider than year ago loss of 28 cents 
On a reported basis  the company posted a loss of 39 cents per share 

The company generated revenues of  6 8 million in the quarter  in line with the Zacks Consensus Estimate  Reported revenues were up from the prior year figure of  1 2 million 
The Quarter in Details
Net sales of Auryxia in the U S  were about  5 6 million  up from  4 8 million in the previous quarter  The drug s prescriptions were approximately 9 150  up 17  sequentially  driven in part by continued gains from new prescribers and an increase in the number of prescriptions per prescriber  The company gained EU approval for Auryxia  under the trade name Fexeric  in Sep 2015  It is now looking for pan European or regional partners for the commercialization of the drug in the region 
The company recorded license revenues of  1 2 million 
Meanwhile  ferric citrate  the compound name for Auryxia in additional indications  is being evaluated in a phase III study for the treatment of iron deficiency anemia  IDA  in patients suffering from stage III V non dialysis dependent chronic kidney disease  NDD CKD   The company reported positive data from the trial that demonstrated statistically significant differences from placebo in the primary as well as all the pre specified secondary endpoints 
These results should support Keryx s plans to submit a supplemental new drug application  sNDA  in the third quarter of 2016  through which it intends to expand the ferric citrate s label to include the treatment of IDA in patients with stage III V NDD CKD 
Research and development expenses declined 20 6  year over year to  7 6 million  primarily due to a decrease in costs associated with the company s recently completed phase III trial evaluating ferric citrate for the treatment of IDA stage III V NDD CKD in adults 
Selling  general and administrative expenses were  20 8 million  up 10 2   primarily related to incremental costs associated with the hiring and onboarding of Keryx s expanded field team 
2016 Guidance Reiterated
Keryx continues to expect Auryxia sales in the U S in the range of  31  34 million  It projects sales to ramp up throughout the year  as the company realizes the full impact of its expanded sales force  Notably  Keryx completed its sales force expansion in 2015  whereby the company now has some 95 sales representatives pitching in for the drug  The company expects cash operating expenses in the range of  87 million to  92 million 
Our Take
Keryx reported in line results for the first quarter  The sequential improvement in Auryxia revenues was encouraging  Going forward  growth should be driven by the sales force expansion in 2015  which will increase the company s reach and frequency of contact with physicians  dieticians and the entire dialysis care team  Meanwhile  a potential approval of the compound for IDA in patients suffering from stage III V NDD CKD will further boost sales  The company is gearing up for a potential launch in 2017 for this indication 
Keryx carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include ArQule  Inc    NASDAQ ARQL    Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   and Shire plc   NASDAQ SHPG    All the stocks sport a Zacks Rank  1  Strong Buy  
 We are reissuing this article to correct a mistake  The original article  issued on Apr 28  2016  should no longer be relied upon  ",2016-04-29,Zacks Investment Research,"https://www.investing.com/analysis/keryx-(kerx)-q1-loss-in-line,-auryxia-up-on-strong-demand-(revised)-200127131",200127131
4236,225751,ARQL,Repros  RPRX  Q1 Loss Narrower Y Y  Pipeline In Focus,opinion,Repros Therapeutics Inc    NASDAQ RPRX   reported a loss of 20 cents per share in the first quarter of 2016  significantly narrower than the year ago loss of 35 cents mainly due to lower research   development  R D  expenses  First quarter revenues  interest income  increased to  17 000 from  1 000 in the year ago period R D costs decreased 48 6  year over year to  3 8 million reflecting lower development expenses related to the enclomiphene product candidate  R D payroll and benefits expenses and legal expenses  partially offset by higher development expenses related to Proellex  General and administrative expenses also decreased 9  year over year to  1 1 million Proellex is being evaluated for uterine fibroids and endometriosis Enclomiphene  which was issued a complete response letter  CRL  by the FDA in late 2015  is being developed for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function  Repros is currently conducting a phase II double blind  placebo controlled  proof of concept study  ZA 205   in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen  Six month data is expected in the third quarter of 2016  Considering that Repros has no approved product in its portfolio at the moment  investor focus will remain on pipeline updates and cash burn Repros is a Zacks Rank  2  Buy  stock  Some better ranked stocks in the health care sector are Apricus Biosciences  Inc    NASDAQ APRI    ArQule Inc    NASDAQ ARQL   and BioSpecifics Technologies Corp    NASDAQ BSTC    All three carry a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-10,Zacks Investment Research,"https://www.investing.com/analysis/repros-(rprx)-q1-loss-narrower-y-y,-pipeline-in-focus-200129392",200129392
4237,225752,ARQL,Catalyst  CPRX  Posts In Line Q1 Loss  Firdapse In Focus,opinion,"Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   reported a loss of 7 cents per share in the first quarter of 2016  which was wider than the year ago loss of 6 cents but in line with the Zacks Consensus Estimate 

Being a development stage company  Catalyst Pharma does not have any approved product in its portfolio yet 
Quarter in Detail
Research and development  R D  expenses were  3 5 million  up 50 9  from the year ago quarter primarily due to activities related to an expanded access program for Firdapse  including manufacturing of the drug  and increased activities associated with other ongoing studies and trials 
General and administrative expenses were up 38 5  to  2 7 million  Expenses rose primarily due to higher pre commercialization expenses  and an increase in headcount  payroll and benefit expenses 
Pipeline Update
In a major setback  the company received a  refusal to file  letter from the FDA in Feb 2015 in connection with its new drug application  NDA   for its lead candidate  Firdapse  The FDA had determined that the application was not sufficiently complete after a preliminary review 
Catalyst recently announced that it held a meeting with the agency to get better clarity on the agency s requirements  The FDA informed the company that it needs positive results from an additional adequate and well controlled study in patients with Lambert Eaton myasthenic syndrome  LEMS   in addition to previously submitted results from the phase III LMS 002 trial 
The company is currently in discussions with the FDA regarding the protocol and logistics for this confirmatory study  The agency is also ready to discuss a design that could efficiently accomplish the requirement with a small  short term study  It has also requisitioned several additional short term toxicology studies  which are expected to be initiated soon 
Meanwhile  the company is evaluating Firdapse for the treatment of certain types of congenital myasthenic syndromes  CMS  and a specific form of myasthenia gravis  The company has initiated an investigator sponsored study of the candidate for the symptomatic treatment of MuSK antibody positive myasthenia gravis  MuSK MG  in Feb 2016 and top line results from this study are expected in 2017 
The company had earlier planned to conduct a phase I dose ranging study in 2016 on its other candidate  CPP 115  at lower doses  subject to the availability of funding  and a phase II trial on the candidate which is being evaluated for the treatment of epilepsy and other selected neurological indications  such as complex partial seizures and Tourette s disorder 
Our Take
Catalyst Pharma s first quarter results were on par with estimates  Going ahead  we expect investor focus on updates regarding the additional study on Firdapse as requisitioned by the FDA  As the company is required to conduct additional studies per the FDA s requirement  this will not only mean additional costs but further delay the NDA resubmission 
On the other hand  R D spend for 2016 would increase due to continued clinical development efforts for Firdapse  including the recently initiated clinical trial for CMS in a pediatric population and a clinical program for MuSK MG among others 
Currently  Catalyst Pharma carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include ArQule  Inc    NASDAQ ARQL    Shire plc   NASDAQ SHPG   and Abbott Laboratories   NYSE ABT    All three stocks sport a Zacks Rank  2  Buy  ",2016-05-11,Zacks Investment Research,"https://www.investing.com/analysis/catalyst-(cprx)-posts-in-line-q1-loss,-firdapse-in-focus-200129431",200129431
4238,225753,ARQL,Notable earnings before Wednesday s open,news,AAWW  ACCO  ADP  AMRN  ANGI  ARCC  ARCO  ARQL  ASC  AVA  BCC  BDC  BERY  BG  BPMC  CDW  CG  CLH  CLX  CNK  CPK  CRCM  CRTO  CVLT  DHX  DLPH  DNOW  DOC  EE  EL  EMES  ENBL  ENR  EXC  FMS  FUN  GIB  GLDD  GRMN  GRPN  HFC  HRS  HSC  HSNI  HUM  ICE  INGR  INXN  ITG  KLIC  LFUS  MMP  MTOR  NCI  NI  NYT  OCN  ORBK  PPP  Q  RAI  S  SBGI  SCMP  SMP  SO  SPR  SR  SSTK  STRA  STRL  SUM  TAP  TWX  USAK  VOYA  VRTV  VSH  WCG  WD  YUM Now read  Physicians Realty  Attractive Yield And Defensive Growth,2017-05-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/notable-earnings-before-wednesdays-open-479532,479532
4239,225754,ARQL,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 02 ,news,"Investing com   U S  stocks were higher after the close on Friday  as gains in the Telecoms  Consumer Goods and Technology sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average gained 0 02  to hit a new all time high  while the S P 500 index added 0 17   and the NASDAQ Composite index added 0 41  
The best performers of the session on the Dow Jones Industrial Average were  Verizon Communications  Inc  NYSE VZ   which rose 1 51  or 0 73 points to trade at 49 19 at the close  Meanwhile   Boeing Co   NYSE BA  added 1 11  or 1 90 points to end at 172 71 and  Home Depot  Inc  NYSE HD  was up 1 03  or 1 46 points to 143 00 in late trade 
The worst performers of the session were UnitedHealth Group Incorporated  NYSE UNH   which fell 3 68  or 6 03 points to trade at 157 62 at the close   Exxon Mobil  Corporation  NYSE XOM  declined 0 66  or 0 54 points to end at 81 76 and Walt  Disney  Company  NYSE DIS  was down 0 59  or 0 65 points to 110 06 
The top performers on the S P 500 were Kraft Heinz Co  NASDAQ KHC  which rose 10 64  to 96 57  VF Corporation  NYSE VFC  which was up 4 59  to settle at 52 68 and Colgate Palmolive Company  NYSE CL  which gained 4 32  to close at 71 98 
The worst performers were  Campbell Soup  Company  NYSE CPB  which was down 6 51  to 58 48 in late trade  Flowserve Corporation  NYSE FLS  which lost 4 80  to settle at 48 37 and  General Mills  Inc  NYSE GIS  which was down 3 75  to 59 23 at the close 
The top performers on the NASDAQ Composite were  MoSys  Inc  NASDAQ MOSY  which rose 54 19  to 3 5000   LMI Aerospace  Inc  NASDAQ LMIA  which was up 48 64  to settle at 13 66 and  Atlantic Alliance Partnership Corp   NASDAQ AAPC  which gained 42 35  to close at 25 62 
The worst performers were X T L Biopharmaceuticals Ltd  NASDAQ XTLB  which was down 34 92  to 2 330 in late trade   ArQule  Inc  NASDAQ ARQL  which lost 18 37  to settle at 1 200 and Aoxin Tianli Group Inc  NASDAQ ABAC  which was down 16 92  to 2 7000 at the close 
Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1722 to 1495 and 45 ended unchanged  on the Nasdaq Stock Exchange  1431 rose and 1050 declined  while 143 ended unchanged 
Shares in Kraft Heinz Co  NASDAQ KHC  rose to all time highs  up 10 64  or 9 29 to 96 57  Shares in Boeing Co  NYSE BA  rose to all time highs  up 1 11  or 1 90 to 172 71  Shares in Home Depot Inc  NYSE HD  rose to all time highs  up 1 03  or 1 46 to 143 00  Shares in MoSys Inc  NASDAQ MOSY  rose to 52 week highs  gaining 54 19  or 1 2300 to 3 5000  Shares in LMI Aerospace Inc  NASDAQ LMIA  rose to 52 week highs  up 48 64  or 4 47 to 13 66  Shares in ArQule Inc  NASDAQ ARQL  fell to 52 week lows  down 18 37  or 0 270 to 1 200  Shares in Atlantic Alliance Partnership Corp  NASDAQ AAPC  rose to all time highs  gaining 42 35  or 7 62 to 25 62  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 3 32  to 11 37 
Gold Futures for April delivery was down 0 40  or 4 95 to  1236 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in March rose 0 11  or 0 06 to hit  53 42 a barrel  while the April Brent oil contract rose 0 23  or 0 13 to trade at  55 78 a barrel 
EUR USD was down 0 55  to 1 0615  while USD JPY fell 0 36  to 112 84 
The US Dollar Index Futures was up 0 42  at 100 87 ",2017-02-17,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-higher-at-close-of-trade;-dow-jones-industrial-average-up-0.02-460712,460712
4240,225755,ARQL,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  TRXC  73   EXEL  28   ARQL  9   FPRX  9   NVCR  9  Losers  ROKA  14   AKER  11   BOLD  11   TGTX  10   OREX  9  Now read ,2017-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-542112,542112
4241,225756,ARQL,Premarket analyst action   healthcare,news,ArQule   NASDAQ ARQL  upgraded to Buy with a  5  285  upside  price target by Needham BioMarin Pharmaceutical  NASDAQ BMRN  upgraded to Outperform with a  110  26  upside  price target by Wedbush Esperion Therapeutics  NASDAQ ESPR  upgraded to Strong Buy with an  81  42  upside  price target by Needham GW Pharmaceuticals  NASDAQ GWPH  upgraded to Buy with a  174  40  upside  price target by Goldman Sachs  NYSE GS   Community Health  Systems  NYSE CYH  downgraded to Underweight by JPMorgan  NYSE JPM  with no price target citing no benefit from tax reform  high degree balance sheet leverage and structural changes in the hospital sector Spark Therapeutics  NASDAQ ONCE  downgraded to Neutral with a  58  26  upside  price target by Goldman Sachs  Tenet Healthcare   NYSE THC  downgraded to Underweight by JPMorgan with a  15  flat  price target for the same reasons cited for CYH Now read ,2017-12-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-991762,991762
4242,225757,ARQL,ArQule reports Q4 results  updates guidance,news,ArQule   ARQL  Q4 results  Revenues   0  R D Expense   4 7M   24 2    SG A   1 8M   2 2    Operating Loss    6 6M    4 3    Net Loss    7 8M    14 7    Loss Per Share    0 09    10 0    Quick Assets   48M   54 3   2018 Guidance  Revenues   3M   4M  Net Loss    27M   30M   Loss Per Share    0 30      0 34   Cash and marketable securities   23M   25M  Net cash used   26M   28M Now read ,2018-03-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/arqule-reports-q4-results-updates-guidance-1324528,1324528
4244,225759,ARQL,Premarket Losers as of 9 05 am  5 18 2018 ,news,ARQL  9  after registering 10 6M shares for sale by certain stockholders CPB  8  on Q3 earnings TNTR  8  CHKR  8  JWN  8  on Q1 earnings AMAT  6  on Q2 earnings INSY  6  on Ad Com doc release RIOT  5  BOOT  5  after launching a 7 21M share public offering for selling stockholders BIDU  5  after Qi Lu steps out of COO role  Now read ,2018-05-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-5182018-1453626,1453626
4248,225763,ARQL,Valeant  VRX  Stock Down On Bleak View  Q1 Earnings Miss,opinion,Shares of Valeant Pharmaceuticals International  Inc    NYSE VRX   were down 14 6  after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises  Its first quarter results were dismal as well  adding to the company s woes Quarterly ResultsEarnings of  1 27 decreased from  2 02 in the year ago quarter and missed the Zacks Consensus Estimate of  1 42  However  revenues of  23 7 million were up from  21 7 million in the year ago quarter and above the Zacks Consensus Estimate of  23 4 million Revenues in the Developed markets were  1 9 billion  up 11  driven by acquisitions  However  the dermatology business remained under pressure  Launch of the Walgreens business led to flat volumes and lower average selling prices  Revenues from Emerging markets were  442 million Cost of goods sold increased to 27  from 24  in the year ago quarter primarily due to unfavorable foreign exchange rates  lower high margin dermatology revenues due to changing market dynamics  and the addition of lower margin products acquired in 2015 Selling  general and administrative expenses increased 42  to  813 million Lowered GuidanceThe company has lowered its guidance yet again  Revenues are now expected in the range of  9 9 billion to  10 1 billion  down from the prior projection of  11 0  11 2 billion  Earnings per share are anticipated to be  6 60 to  7 00  down from the previous guidance of  9 50  10 50 The dermatology and gastrointestinal businesses continue to face challenges from lower script volume  a decline in fill rates  decreased ASPs and overall higher managed care rebates  The Salix business  on the other hand  is performing beyond management s expectations Our TakeOnce an acquisition giant  woes do not seem to end for Valeant  The company has been under the spotlight since Aug 2015 for all the wrong reasons including price hike of specialty drugs  erroneous financial reporting  and termination of contracts with Philidor Rx Services  However  at every turn  it seems that the going just gets tougher for Valeant  Earlier  the company had delayed its earnings release due to the review of certain accounting practices  Valeant has also received a notice of default from its debtors As if the delayed results were not enough  the slash in guidance hints at more troubled conditions ahead According to the new CEO  Joseph Papa  the first quarter results reflect the impact of a significant disruption that the pharmaceutical company has faced over the past nine months  Management transition issues  heavy debt levels and persistent organizational distractions are expected to impact its results even further  going ahead Valeant currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include Abbott Laboratories   NYSE ABT    ArQule Inc    NASDAQ ARQL   and Johnson   Johnson   NYSE JNJ    All three stocks carry a Zacks Rank  2  Buy  ,2016-06-07,Zacks Investment Research,"https://www.investing.com/analysis/valeant-(vrx)-stock-down-on-bleak-view,-q1-earnings-miss-200134848",200134848
4249,225764,ARQL,ArQule strengthens executive team with two key appointments,news,ArQule   NASDAQ ARQL  announces two strategic additions to       its executive team  appointing Dr  Marc Schegerin as Senior VP  Corporate Strategy  Communication   Finance  and Dr        Shirish Hirani as Senior VP  Program Management and Product Planning  Dr  Schegerin  prior to       ArQule  was a Healthcare Investment Banking Director at        Citigroup   NYSE C   Dr  Hirani  until recently was at ARIAD Pharmaceuticals as Vice       President  Drug Development  Now read ,2018-05-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/arqule-strengthens-executive-team-with-two-key-appointments-1461149,1461149
4257,225772,ARQL,ArQule  Bruised But Not Done ,opinion,Bruised but not doneIn the wake of the failed MARQUEE and suspended ATTENTION Phase III trials in NSCLC  ArQule  ARQL  and its partners have switched the focus of tivantinib to HCC  A pivotal Phase III trial in this indication will be initiated in early 2013  the outcome of which is now central to ArQule s investment case  Other trial data that could affect the shares include mCRC and mCRPC  sponsored by NIH CRADA   Cash at end 2012 will be   130m  but ArQule may need to raise additional funds to support tivantinib and other drug candidates  development before tivantinib s potential launch in 2016  Our valuation is  376m or  5 4 share Focus on  c Met high  hepatocellular carcinomaThe failure of tivantinib in the MARQUEE and ATTENTION trials in NSCLC and  by contrast  the robust Phase II data in second line HCC  have prompted ArQule to focus on the liver cancer indication as the drug s path to approval  ArQule and its partner  Daiichi Sankyo  have obtained a special protocol assessment  SPA  from the FDA for the Phase III trial  which will compare tivantinib to placebo in second line patients with high levels of c Met   c Met high    The trial will start in early 2013 and complete in 2015  leading to a potential approval in the US and EU in 2016 mCRC may surpriseA Phase II of tivantinib in combination with irinotecan Erbitux in metastatic colorectal cancer is due to render data in the next few months  If positive  it could present a second potential registration indication  However  a Phase III trial in this indication would be unlikely to start until after 2013 Cash adequate  for nowArQule expects to end 2012 with close to  130m in cash  which should be enough to support operation into 2015  Future milestone payments are likely to be used to pay for ArQule s share of tivantinib clinical costs  The company may  however  have to raise additional funds prior to tivantinib s launch Valuation   376m with upside potentialWe value ArQule at  376m or  5 4 per share  fully diluted   based on our risk adjusted DCF model  This includes tivantinib rNPV at  221m  an indicative contribution from other pipeline assets of  25m and year end net cash of  130m  Our value of ArQule is significantly higher than its market cap  suggesting potential for share appreciation To Read the Entire Report Please Click on the pdf File Below ,2012-11-27,Edison,https://www.investing.com/analysis/arqule:-bruised-but-not-done-145220,145220
4258,225773,ARQL,ArQule Shares Bottom Out After Encouraging ASCO Data,opinion,ArQule  ARQL  is a drug developer with a market cap of about  340 million  It has a pipeline containing five separate drugs  The most important of these  to investors  is tivantinib  ARQ 197   which is a c MET inhibitor being developed for the treatment of hepatocellular carcinoma  HCC  as well as lung cancer  for which there are two phase III trials underway   HCC is the most common type of liver cancer in the world  responsible for more than 90  of the 749 000 new cases worldwide each year Tivantinib s mechanism is based on more recent studies on c MET  where researchers have found that the protein is used as a method of provoking angiogenesis in cancer cells  Angiogenesis is a term used to describe the growth of new blood vessels  which is a way that cancer cells feed the growth of a tumor Other proteins that have already been heavily studied  like VEGF  have been targeted by the angiogenetic inhibition drug market  The drug bevacizumab  Avastin  for instance  has been marketed by Genentech  RHHBY PK  with success  Tivantinib  among other new angiogenic inhibitors  are hence targeting c MET in the hopes that this will disable one pathway by which cancer cells have been supporting proliferation On June 2nd  at the 48th annual meeting of the American Society of Clinical Oncology  ASCO   ArQule has released positive phase II study results for Tivantinib for the treatment of hepatocellular carcinoma conducted by Daiichi Sankyo  The phase II trials were conducted with 107 HCC patients who had inoperable tumors and had disease progression following first line therapy  or were deemed incapable of tolerating first line therapy  The primary endpoint was the TTP  time to progression  in the ITT  intent to treat  population  which was met with success A statistically significant 56  improvement relative to the placebo group was seen in the  time to progression   or  test  population  Another encouraging statistic was the median TTP in the tivantinib arm  which was recorded as 2 9 months relative to the 1 5 months in the placebo arm representing a significant average slowing of HCC  This equated to a hazard ratio of  43 The Monday following the Saturday  June 2nd  on which the encouraging phase II statistics were revealed  the stock jumped almost 3  and looked like it was set to begin a rebound after the  20  drop it has experienced in the last month  but shares are once again back down to  bottom  levels A moderate 5 8  of the shares are being shorted right now  and it s possible that shorts may be discouraged in anticipation of tivantinib s interim phase III results for the MARQEE study  studying tivantinib in non small cell lung cancer  NSCLC   This phase III data should be a major market catalyst looking forward  and should be released well before 2013 ,2012-06-27,Myriad Equity,https://www.investing.com/analysis/arqule-shares-bottom-out-after-encouraging-asco-data-127862,127862
4260,225775,ARQL,The Medicines Co  s Carbavance Scores In Phase III Study,opinion,The Medicines Company   NASDAQ MDCO   got some good news on the pipeline front with its experimental antibiotic  Carbavance meeting FDA as well as EMA pre specified primary endpoints in a late stage study  TANGO I  conducted in patients with complicated urinary tract infections  cUTI  Top line results from the multi center  randomized  double blind  double dummy study showed that Carbavance achieved statistical superiority over piperacillin tazobactam  trade name  Zosyn  with overall success being observed in 98 4  of patients treated with Carbavance  Carbavance s safety and tolerability was comparable to the control treatment The company believes that this data is sufficient to seek regulatory approval in both the U S  and the EU next year with the U S  submission expected in early 2017  Full results from the study will be presented at an upcoming infectious disease conference Carbavance has been designated a Qualified Infectious Disease Product by the FDA and has fast track status as well  Antibiotic resistance  especially to carbapenems  is a rapidly growing problem with carbapenem resistant enterobacteriaceae  CRE  infections being one of the deadliest given the mortality rate of 40   As a result  there is urgent need for antimicrobials that can effectively treat CRE and other resistant organisms Carbavance is one of the four potential blockbuster candidates in The Medicines Co  s pipeline  It is currently in the phase III multi center  randomized  open label TANGO 2 study in which it is being compared to  best available therapy  in subjects with selected serious infections due to CRE  Interim analysis from this study is expected to provide supportive data for the regulatory application in the U S Meanwhile  The Medicines Co  expects important news flow on its three other blockbuster potentials   ABP 700  IV anesthetic and sedation agent   ALN PCSsc  hypercholesterolemia   and MDCO 216  lipid modulating agent    in the second half of the year The Medicines Co  is a Zacks Rank  4  Sell  stock  With its flagship product Angiomax going generic  the company has entered a challenging period where driving top line growth will become increasingly difficult  In such a scenario  investor focus will remain on the company s pipeline Some better ranked stocks in the healthcare sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    ArQule Inc    NASDAQ ARQL   and Apricus Biosciences  Inc    NASDAQ APRI     while ANI is a Zacks Rank  1  Strong Buy  stock  ArQule and Apricus are Zacks Rank  2  Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-27,Zacks Investment Research,https://www.investing.com/analysis/the-medicines-co.'s-carbavance-scores-in-phase-iii-study-200138780,200138780
4262,225777,ARQL,4 Stocks To Watch Today  CASI  CRC  LGCY  PSTG,opinion,"Casi Pharma  NASDAQ CASI  popped and broke out  and I put a swing on it  I like the wedge that s forming  It looks like it s about to explode out of it  We ll see  On Tuesday  it was up 41 cents or 6 39   to 6 93  and the volume picked up to nearly a million shares  It needs to get up through 7 1 2  and then my targets will be upward of 9 1 2 10 
California Resources Corp  NYSE CRC  is continuing to push  jumping 55 cents  or 2 45   to 22 96  on 1 2 million shares on Tuesday  It s been up seven days in a row and up through a couple layers of resistance  If it gets through here  it should test the January highs at 22 95  and above that  I think it s clear sailing to 30  or better 
Legacy Reserves LP  NASDAQ LGCY  is really a nice  little  junior oil stock  After the breakout  I gave you a swing on it  and it got up to my first target on Tuesday  which was around 6 1 2 3 4  and it got up to 6 1 4  gaining 13 cents  or 2 3   to 5 78  on a million shares  You can see the line of resistance  If it can back and fill for a few days  and not go down too much  you could very well see 8  and 9 1 2 on this one 
Pure Storage Inc  NYSE PSTG  popped out of the falling wedge on Tuesday  jumping 1 29  or 6 6   to 20 77  on 3 8 million shares  and held the channel bottom as well  It looks like it should make a run as early as Wednesday to 21 40  If it gets through that  maybe it will even get up to 22 50  Ultimately  we re looking for a run to the top of the channel in the 25 6 range 
Stocks on the long side included ArQule Inc  NASDAQ ARQL   Casa Systems  Inc   CASA   CASI Pharmaceuticals  Inc   CASI   Clearside Biomedical Inc  NASDAQ CLSD   California Resources Corporation  CRC   Carvana Co   CVNA   eGain Corporation  EGAN   First Solar  Inc   NASDAQ FSLR   Intelsat Sa  NYSE I   IntriCon Corporation  IIN   Immunomedics Inc   IMMU   Direxion Daily S P Biotech Bull 3X ETF  LABU   Legacy Reserves LP  LGCY   Match Group  Inc   NASDAQ MTCH   Novanta Inc   NOVT   Nutanix  Inc   NTNX   NovoCure Limited  NVCR   Pure Storage  Inc   PSTG   Qualys  Inc   QLYS   Roku  Inc   ROKU   Rayonier Advanced Materials  NYSE RYAM   Sailpoint Technologies Holdings Inc  NYSE SAIL   Twitter  Inc   TWTR   and Xencor  Inc   XNCR  ",2018-04-18,Harry Boxer,https://www.investing.com/analysis/casi-crc-lgcy-pstg-200306380,200306380
4263,225778,ARQL,What s In The Cards For Merck KGaA  MKGAF  In Q1 Earnings ,opinion,"Merck  NYSE MRK  KGaA  is scheduled to report first quarter 2018 results on May 15 Merck s shares have declined 11 1  so far this year against the  s rally of 0 8  The company reports results under three business sectors   Healthcare  Life Science and Performance Materials Merck s revenues were driven by organic sales growth in its Healthcare and Life Science segments in the fourth quarter  We expect to see the same trend in the upcoming quarterly results In December 2017  Merck s multiple sclerosis drug  Mavenclad was approved in Australia and Canada  following its approval in Europe in the third quarter of 2017  The expansion in new geographies is likely to boost sales of the drug in the to be reported quarter Moreover  in 2017  Bavencio was approved in the United States  Europe and Japan for Merkel cell carcinoma  The drug was also approved for advanced bladder cancer in the United States in 2017  Healthcare sales are likely to get a boost  The company develop Bavencio in partnership with Pfizer Inc    NYSE PFE   for several cancer indications Sales of three key drugs   Rebif  Erbitux and Gonal f   are expected to be lower in first quarter 2018  The downside is likely to be caused by persistent competitive pressure and price reduction  Moreover  unfavorable currency movement is anticipated to dent the top line Moreover  operating expenses increased in 2017 due to new launches and higher pipeline development cost  Expenses are estimated to increase in the first quarter as the company focuses on the development of an innovative pipeline  launch of Bavencio in new geographies as well as Mavenclad In 2017  the company divested its biosimilar business and is currently considering strategic options for its Consumer Health segment Merck is also focused on the development and protection of its novel DNA sequencing technology   CRISPR  In February  the technology was issued patents in Korea and Israel  This can also increase the expense for the company We expect management to shed light on the progress and commercialization plans for Bavencio on the earnings call  The company is likely to provide updates on its strategic plans Merck KGaA Price and EPS Surprise
    Stocks that Warrant a LookHere are a couple of healthcare stocks that you may want to consider  as our model shows that these have the right combination of elements   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to post an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Summit Therapeutics PLC   NASDAQ SMMT   is expected to release results on Jun 13  The company has an Earnings ESP of  9 51  and carries a Zacks Rank  3  You can see  ArQule  Inc    NASDAQ ARQL   is expected to release second quarter results on Aug 3  The Zacks  2 Ranked company has an Earnings ESP of  140  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-13,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-merck-kgaa-mkgaf-in-q1-earnings-200316005,200316005
4264,225779,ARQL,4 Stocks Breaking Good This Week  AQMA  ATRA  TWMJF  XNCR,opinion,"Aqua Metals Inc  NASDAQ AQMS   which we have a swing on  broke out  pulled back  formed a wedge  and broke back out again on Monday  popping 42 cents  or 12   to 3 97  on nearly a million shares  What I need is a move over 4 22  If it gets through that  it should get up to the 5 3 4 6 range  The secondary target is above 8 00 
Atara Biotherapeutics Inc  NASDAQ ATRA  finally broke out of the big coil on Monday that we were talking about over the last few months  jumping 1 40  or 2 8   to 51 45  on 1 2 million shares  Over the last two months  it has been consolidating the big move it had in Dec  Jan  and Feb  It s been up nine days in a row  and pulled back at the end of the day on Monday  but it still closed to the upside on the session  I m looking for a target of 59 60  but it may get a pullback entry opportunity 
Canopy Growth Corp  OTC TWMJF   a marijuana stock  has been up three days in a row  It was coming out of a consolidation on Monday  and jumped 2 35  or 8 39   to 30 35  on 2 3 million shares  It s still up against key resistance  However  if it gets through the 32 33 zone  this could be a 45 48 dollar stock 
Xencor Inc  NASDAQ XNCR  has been up nearly every day in the last two weeks except for Thursday  On Monday  it popped another 1 11  or 3 24   to 35 34  on 332 637 shares traded  It looks to me like this is headed to 42  Eventually  I would be looking for 49 and 55 
Stocks on the long side included ACBFF   Aqua Metals  AQMS   ArQule Inc  NASDAQ ARQL   Atara Biotherapeutics  Inc   ATRA   Codexis Inc  NASDAQ CDXS   California Resources Corporation  CRC   Cree  Inc   CREE   Ceragon Networks Ltd   CRNT   Endologix Inc  NASDAQ ELGX   Foundation Medicine  Inc   FMI   Intelsat S A   I   Renewable Energy Group  Inc   REGI   Resonant Inc   RESN   Teladoc  Inc   TDOC   T2 Biosystems  Inc   TTOO   Canopy Growth Corporation  TWMJF   VelocityShares 3x Long Crude linked to S P GSCI Crude Oil Excess Return  NYSE UWT   W T Offshore  Inc   WTI   Xencor  Inc   XNCR   YRC Worldwide Inc  NASDAQ YRCW  ",2018-05-21,Harry Boxer,https://www.investing.com/analysis/aqma-atra-twmjf-xncr-200318054,200318054
4273,225788,ARQL,4 Stocks To Watch  MRTX  TNDM  EBIX  OSTK,opinion,"Mirati Therapeutics  Inc   NASDAQ MRTX  popped 1 40 or 4   to 37 20  on 275 316 shares traded on Tuesday above the 37 60 65 range  It got up as high as 38 20 and backed off a dollar  Still  if it follows through  I m looking for a move to about the 43 range  and then 52 longer term 
Tandem Diabetes Care  Inc   NASDAQ TNDM  just won t quit  jumping another 72 cents  or 5 86   to 13 01  on 1 54 million shares on Tuesday  After a day of consolidation  it punched back up again  If it doesn t get through here  it may pull back  Momentum could carry it to 14 1 2  and then 17 going forward 
Stocks on the Short Side  
Ebix  Inc   NASDAQ EBIX   which I gave a short on around mid April  went up a little higher  above the 50 day  but now it s come down again  three days in a row of the last seven days  and on Tuesday  it dropped another 45 cents to 73 25 on 132 063 shares traded  It looks to me like the fishbowl is over  If it takes out 72  it s headed for 69  65  or lower  maybe much lower 
Overstock com  Inc   NASDAQ OSTK  lost another 1 05 or 2 82   to 36 25  1 56 million shares on Tuesday  It looks like it s 4 waves down  If that breaks  I m looking for the 20 22 zone as the next target going forward 
Stocks on the long side included ArQule  Inc   NASDAQ ARQL   Endologix  Inc   NASDAQ ELGX   Health Insurance Innovations  Inc   NASDAQ HIIQ   iQIYI  Inc   NASDAQ IQ   Mirati Therapeutics  Inc   NASDAQ MRTX   Micron Technology  Inc   NASDAQ MU   Quotient Limited  NASDAQ QTNT   Recro Pharma  Inc   NASDAQ REPH   Tandem Diabetes Care  Inc   NASDAQ TNDM   Canopy Growth Corporation  OTC TWMJF   21Vianet Group  Inc   NASDAQ VNET   Energous Corporation  NASDAQ WATT   and Xencor  Inc   NASDAQ XNCR  
On the short side  stocks included Alnylam Pharmaceuticals  Inc   NASDAQ ALNY   Bitauto Holdings Limited  NYSE BITA   The Clorox Company  NYSE CLX   Ebix  Inc   NASDAQ EBIX   Edgewell Personal Care Company  NYSE EPC   Essent Group Ltd   NYSE ESNT   Finisar Corporation  NASDAQ FNSR   iRobot Corporation  NASDAQ IRBT   Overstock com  Inc   NASDAQ OSTK   Radian Group Inc   NYSE RDN   Signet Jewelers Limited  NYSE SIG   Silicom Ltd   NASDAQ SILC   Teradyne  Inc   NYSE TER   LendingTree  Inc   NASDAQ TREE   and YY Inc   NASDAQ YY  ",2018-05-22,Harry Boxer,https://www.investing.com/analysis/mrtx-tndm-ebix-ostk-200318484,200318484
4274,225789,ARQL,Stocks   Canopy Growth  ArQule Rise in Premarket  Microsoft Edges Lower,news,"Investing com    Stocks in focus in premarket trade on Monday  9th December 

Marijuana products group   Canopy Growth   Corp  NYSE CGC  rose 5 9  after saying it has hired David Klein to be its new CEO  Klein is currently chief financial officer at brewer Constellation Brands  NYSE STZ   whose stock was unchanged on the news 


U K  supermarket chain   Tesco    OTC TSCDY   LON TSCO  rose 5 2  after confirming that it s considering a sale of its remaining Asian businesses  estimated by analysts to be worth around  9 billion 


Microsoft  NASDAQ MSFT  edged down 0 3  after a report that China is accelerating efforts to remove U S  computers and software from government offices and public institutions 


Cancer drug maker   Synthorx    NASDAQ THOR  rose some 170  after agreeing to be bought by French pharma giant   Sanofi    NASDAQ SNY  for some  2 5 billion


  ArQule    NASDAQ ARQL   another oncology specialist  also more than doubled after agreeing to be bought by Merck   Co  NYSE MRK  for  2 7 billion ",2019-12-09,Investing.com,https://www.investing.com/news/stock-market-news/stocks--canopy-growth-arqule-rise-in-premarket-microsoft-edges-lower-2036886,2036886
4280,225795,ARQL,Kinase inhibitors in focus on after Merck bid for ArQule,news,"Merck s  2 7B bid for ArQule is yet another example of Big Biopharma s high regard for oral kinase inhibitors for treating cancer  ArQule s lead drug is ARQ 531  an oral inhibitor of Bruton s tyrosine kinase  BTK  
Previous deals include Pfizer s  PFE  0 1    10 4B takeout of Array BioPharma and its lineup of tyrosine kinase inhibitors  TKIs   finalized in July  and Eli Lilly s  LLY  0 2    8B acquisition of Loxo Oncology in February and its portfolio of RET  TRK and BTK inhibitor candidates and TRK inhibitor Vitrakvi  larotrectinib   approved in the U S  in November 2018 for TRK fusion cancers 
AbbVie  ABBV  0 1   bought Pharmacyclics for  21B in 2015 in order to secure the rights to BTK inhibitor Imbruvica  ibrutinib   sharing profits with Johnson   Johnson  JNJ  0 1   
AstraZeneca  AZN  0 2   acquired a majority stake in Acerta Pharma for  4B late 2015 for access to its kinase inhibitor lineup  Its first win was BTK inhibitor Calquence  acalabrutinib   approved in the U S  in October 2017 for mantle cell lymphoma and last month for CLL 
Kinase inhibitor related tickers  BeiGene  BGNE  0 6    Principia  Biopharma  PRNB  3 5    Merck KGaA  OTCPK MKGAY   TG Therapeutics  TGTX  30 3    Aptose Biosciences  APTO  37 9    Exelixis  EXEL  1    Deciphera Pharmaceuticals  DCPH  3 8    Curis  CRIS  0 6    Pulmatrix  PULM  1 1    Verastem  VSTM  8 3    BioCryst Pharmaceuticals  BCRX  0 2    Aclaris Therapeutics  ACRS  6 6    IDEAYA Biosciences  IDYA  1 8    Rigel Pharmaceuticals  RIGL  1 4    Astellas Pharma  OTCPK ALPMY   Blueprint Medicines  BPMC  7 4    Seattle Genetics  SGEN  2 7    Spectrum Pharmaceuticals  SPPI  0 3    Puma Biotechnology  PBYI  1    Galapagos NV  GLPG  1 6  ",2019-12-09,Seeking Alpha,https://invst.ly/o-8ft,2037013
4285,225800,ARQL,Do Options Traders Know Something About ArQule  ARQL  Stock We Don t  ,opinion,Investors in ArQule  Inc    NASDAQ ARQL   need to pay close attention to the stock based on moves in the options market lately  That is because the Apr 18  2019  5 00 Call had some of the highest implied volatility of all equity options today What is Implied Volatility Implied volatility shows how much movement the market is expecting in the future  Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other  It could also mean there is an event coming up soon that may cause a big rally or a huge sell off  However  implied volatility is only one piece of the puzzle when putting together an options trading strategy What do the Analysts Think Clearly  options traders are pricing in a big move for ArQule shares  but what is the fundamental picture for the company  Currently  ArQule is a Zacks Rank  3  Hold  in the Medical  Drugs industry that ranks in the Top 20  of our Zacks Industry Rank  Over the last 60 days  one analyst has increased the earnings estimates for the current quarter  while none have dropped their estimates  The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 10 cents per share to a loss of 8 cents in that period Given the way analysts feel about ArQule right now  this huge implied volatility could mean there s a trade developing  Oftentimes  options traders look for options with high levels of implied volatility to sell premium  This is a strategy many seasoned traders use because it captures decay  At expiration  the hope for these traders is that the underlying stock does not move as much as originally expected Looking to Trade Options Each week  our very own Dave Bartosiak gives his top options trades  Check out his recent live analysis and options trade for the NFLX earnings report completely free  See it here   or check out the embedded video below for more details ,2019-04-11,Zacks Investment Research,https://www.investing.com/analysis/do-options-traders-know-something-about-arqule-arql-stock-we-dont-200405828,200405828
4286,225801,ARQL,6 Stocks To Watch  ARQL  AXSM  CATS  RIOT  RLGT  TIGR,opinion,"Markets had a consolidation type session  first up at the opening  sharply lower  then sharply rallying back up  only to pull back a little at the end of the day  It was a decent session for a lot of stocks  We have highlighted quite a few that look like they may be on the verge of breaking out and moving to the next level 
ArQule  Inc   ARQL 
ARQL which had a V bottom in December like many biotechs  and the market in general  popped to resistance and backed off to form a left head right shoulder  formed a big breakaway gap on big volume with a breakout  followed by a month long wedge  and then popped out of the wedge  On Monday  it had a bullish engulfing day  advancing 34 cents  or 6 12   to 5 90  on 1 7 million shares  or 70  more volume than average  If this should get above 6 00  which may happen quickly  targets are 7 1 4  8 1 2  and 9  I think it looks good 
Axsome Therapeutics  Inc   AXSM 
AXSM jumped 85 cents  or 6 32   to 14 31  on 1 8 million shares  I think the wedge is about to come to fruition and breakout  The targets are 16 and 21 going forward 
Catasys  Inc   CATS 
CATS one of our swing trades  climbed 76 cents  or 6 08   to 13 25  on 113 964 shares traded  This stock has been backing and filling in a wedge  I think it s ready to go  It s needs to get above 14 1 2 3 4 to really get going  If it does  targets going forward are 18 and 24 
Riot Blockchain  Inc   RIOT 
RIOT a cryptocurrency company  popped and formed a wedge  gaining 10 cents  or 2 17   to 4 71  on 1 8 million shares on Monday  I m inclined to think that if this breaks out of the wedge  it s just too bullish of a formation  Good volume pattern  good technicals  and good rising OBV  I think the pop and the wedge will lead to about the 6 1 4 1 2 area  maybe 3 4  Then it will go to 8 3 4 9  Those are my targets 
Radiant Logistics  Inc   RLGT 
RLGT a shipping logistics firm  broke out and ran up 38 cents  or 5 74   to 7 00  on 1 7 million shares  It has an amazing base  and now it s coming to a level that I haven t seen it do for four years  It might ramp toward a 7 3 4 8 range  It soared a 52 week high at 7 09 just three days ago and it was right back up there again  Keep an eye on it 
UP Fintech Holding Limited  TIGR 
TIGR since its IPO  has been phenomenal  only pausing for four days because of a falling wedge  It popped out of the wedge and took off  On Monday  it was up another 1 60  9 09   to 19 21  on 2 7 million shares  The target on this one is 22 23 short term 
Stocks on the long side
ArQule  Inc   ARQL   Riot Blockchain  Inc   RIOT   ATA Inc   ATAI   Asure Software  Inc   ASUR   Axsome Therapeutics  Inc   AXSM   Tronox Limited  TROX   Soliton  Inc   SOLY   Bio Path Holdings  Inc   BPTH   Adient plc  ADNT   Boxlight Corporation  BOXL   UP Fintech Holding Limited  TIGR   Conformis  Inc   CFMS   Radiant Logistics  Inc   RLGT   and Catasys  Inc   CATS  
Watch video here ",2019-04-16,Harry Boxer,https://www.investing.com/analysis/arql-axsm-cats-riot-rlgt-tigr-200407000,200407000
4287,225802,ARQL,6 Stocks To Watch  ACB  ARQL  ASUR  ASYS  AXSM  RIOT,opinion,"Marijuana stocks perked up a little bit on Tuesday  Aurora Cannabis Inc   ACB  was one of them  popping 37 cents  or 4 35   to 8 88  on a strong 23 million shares  It s not quite the breakout you want to see  Keep your eye on this one  though  If it breaks out of 9 30  40 in the next couple days  you should see 10  and then 12 1 2  Keep your eye on support as well at 8 35  40 
ArQule  Inc   ARQL 
ARQL broke out on Tuesday  bouncing 75 cents  or 13   to 6 65  on 4 5 million shares  Volume was good  I like the look of it  I think it s a swing  It popped across resistance  and I think it s going retest the spike high at 7 21 from July of last year  which is my immediate target  and then I m looking for 9 1 2 
Asure Software  Inc   ASUR 
ASUR exploded 1 16  or 16 34   to 8 26  on 2 7 million shares  That s the biggest volume I ve ever seen on this stock  I put a swing on it Tuesday  with the kind of volume I saw  and the move  which I thought was huge  It got right to resistance at the gap  and it did back off a little bit  but held onto gains  At this point  I m thinking 9 1 2 and 11 1 2  maybe 3 4 
Amtech Systems  Inc   ASYS 
ASYS has a beautiful base breakout and pullback  This ongoing swing that looks like it broke out of a wedge on Tuesday  gained 20 cents  or 3   to 6 97  on 119 702 shares traded  It should go to 7 1 2  and then 8 3 4  my next two targets 
Axsome Therapeutics  Inc   AXSM 
AXSM another swing that broke out of a coil on Tuesday and popped a little bit was up 1 17  or 8 18   to 15 48  on 1 55 million shares  If it does get a push through 16 3 4  the next target has got to be 20 
Riot Blockchain  Inc   RIOT 
RIOT a swing trade of ours  looks like it s about to explode right out of the wedge that formed  It popped 22 cents  or 4 67  to 4 93  on 1 7 million shares  Targets are in the 6 6 1 4 6 1 2 area  and then 9 00 
Stocks on the long side
Aurora Cannabis Inc   ACB   Advanced Micro Devices  Inc   NASDAQ AMD   ArQule  Inc   ARQL   Asure Software  Inc   ASUR   Amtech Systems  Inc   ASYS   Axsome Therapeutics  Inc   AXSM   EVERTEC  Inc   EVTC   Extreme Networks  Inc   EXTR   Freeport McMoRan Inc   FCX   McDermott International  Inc   MDR   Puxin Limited  NEW   PhaseBio Pharmaceuticals  Inc   PHAS   QUALCOMM Incorporated  NASDAQ QCOM   Riot Blockchain  Inc   RIOT   UP Fintech Holding Limited  TIGR   Viomi Technology Co   Ltd  VIOT   and Western Digital Corporation  NASDAQ WDC  
Watch video here ",2019-04-17,Harry Boxer,https://www.investing.com/analysis/acb-arql-asur-asys-axsm-riot-200407474,200407474
4288,225803,ARQL,6 Stocks To Watch  ARQL  BE  MX  NUS  PRPO  TPB ,opinion,"Markets had a pretty ugly session on Wednesday after the  FOMC and Powell spoke  That late selloff was ugly  the Nasdaq 100 dropping a couple of hundred points in the last hour  the S P 500 just 31  They closed at the lows for the day going away  It is not a good sign after early gains  so it may be a reversal day ahead  We ll have to see  For now  let s take a look at a few we highlighted 
ArQule  Inc   ARQL 
ArQule Inc  NASDAQ ARQL  has been ramping up  and you can see the pullback to the trendline  and then Wednesday s bounce of 38 cents  or 6 37   to 6 35  on 2 25 million shares  This is what you have to watch  6 74 has been the high in the last 2 3 weeks  Wednesday s high was 6 73  If it can get through that  targets are 7 1 4  8 00  and 9 00  potentially 
Bloom Energy Corporation  BE 
Bloom Energy Corp  NYSE BE  had another follow through day on Wednesday with good volume  popping 70 cents  or 5 14   to 14 32  on 2 million shares  I like the way this stock looks  I like the way it s trending  I think it has much more potential  Targets are 16 1 2 and 20 
MagnaChip Semiconductor Corporation  MX 
MagnaChip Semiconductor  NYSE MX  on Wednesday popped 1 11  or 12 54   to 9 96  on 1 4 million shares  This stock looks like it s about to take off  Wednesday s high is 10 43  Over a week ago it traded at 10 45  If it can get through that  targets are 12  and higher 
Nu Skin Enterprises  Inc   NUS 
Nu Skin Enterprises Inc  NYSE NUS  had a major breakaway gap on huge volume on Wednesday  jumping 13 45  or 26 44   to 64 32  on 3 85 million shares  The key for this stock  for me  now is going to be in the 70 74 level  So  those are my targets 
Precipio  Inc   PRPO 
Precipio Inc  NASDAQ PRPO  had a big pop on Wednesday  which is two out of the last three days on huge volume  bouncing 2 35  or 39   to 8 40  on 5 3 million shares  Earlier in the month it exploded from 1 70 to 9 00  and change  and then back down to 4 00  and change  Right now  it seems to me  support is in the 4 40  50 zone  If it gets a spike up on Thursday to 9 9 1 2  this could be 11 or 12 
Turning Point Brands  Inc   TPB 
Turning Point Brands Inc  NYSE TPB   a tobacco marijuana related company  ran up in January  had a 5 wave corrective more  pulled back  and on Wednesday  exploded 7 68  or 18   to 50 45  on 500 000 shares traded  That doesn t sound like a lot of volume  but it s the biggest volume since September  I think we re headed toward 60 
Stocks on the long side
Digital Turbine  Inc   APPS   ArQule  Inc   ARQL   Bloom Energy Corporation  BE   Curaleaf Hldgs Inc   CURLF   Enphase Energy  Inc   ENPH   MagnaChip Semiconductor Corporation  MX   Nanometrics Incorporated  NANO   Nu Skin Enterprises  Inc   NUS   OSI Systems  Inc   OSIS   Precipio  Inc   PRPO   Qudian Inc   QD   Soliton  Inc   SOLY   Turning Point Brands  Inc   TPB   and Veracyte  Inc   VCYT  
Watch video here ",2019-05-02,Harry Boxer,https://www.investing.com/analysis/arql-be-mx-nus-prpo-tpb-200415223,200415223
4289,225804,ARQL,Company News For Jun 17  2019,opinion,Shares of Facebook Inc    NASDAQ FB   gained 2 2  following news that the company has tied up with more than a dozen entities for its new cryptocurrency Libra Bluegreen Vacations Corp    NYSE BXG   shares jumped 31 1  after entering into a settlement with Bass Pro to reinstate marketing activitiesArQule Inc  s   NASDAQ ARQL   shares surged 30 4  after revealing clinical proof of concept data from its ongoing Phase 1 study of ARQ 531Shares of Kura Oncology Inc    NASDAQ KURA   rose 0 5  after its drug Tipifarnib in Peripheral T Cell Lymphona met primary endpoint of phase 2 trial,2019-06-16,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jun-17-2019-200432105,200432105
4290,225805,ARQL,ARQL  CVM  EVBG  JNUG  KL  TLRY   Stock Charts To Watch,opinion,"ArQule  Inc   NASDAQ ARQL  is ramping and getting to the top of the channel  but after the breakaway gap a week ago  it s continuing to push  On Thursday  it pushed another 67 cents  or 7   to 10 35  on 6 3 million shares  It looks like a move to 11 1 2 12 short term may happen 
CEL SCI Corporation  NYSE CVM  has been exploding  and you can see the run up it s had recently  In about three weeks it has gone from 3 70 to 7 70  On Thursday  it ran 96 cents  or 15   to 7 54  on 1 2 million shares  Resistance from the May high is at about 8 1 2  If it gets through that  my targets are 12 and 15 
Everbridge  Inc   NASDAQ EVBG  is a monster  In the past three years it has gone from under 12 to 97  On Thursday  it jumped 5 70  or 6 24   to 97 02  on 1 2 million shares  Currently  it has been breaking out and running up in a juxtaposition with the lines running to about 103 105  which is the target short term 
The Direxion Daily Jr Gold Miners Bull 3X ETF  NYSE JNUG  has a large basing type pattern after a big downtrend  It had a big breakaway gap on Thursday with a pop of 1 64  or 17   to 11 36  on 26 5 million shares  That s huge volume for JNUG  There s some resistance at about 11 3 4  I think this stock will make it to 13 3 4 and 16 
Kirkland Lake Gold Ltd   TSX KL   one of our favorites over the last two years  continues to explode and run beautifully in a rising channel  My target of 40 41 was hit on Thursday when it popped 1 22  or 3   to 41 00  on 1 7 million shares  The next target is 45 
Tilray  Inc   NASDAQ TLRY   a marijuana stock  is looking much better  It broke out on Thursday  gaining 4 24  or 9   to 49 71  on 4 5 million shares and I put a new swing on it  I just like the fact that it took out a 9 month declining topsline  I think it has more to go  Volume was the best in about a week and a half  I m looking for a test of 54  and  potentially  62 
Stocks on the long side included First Majestic Silver Corp   AG   AquaBounty Technologies  Inc   AQB   ArQule  Inc   ARQL   AngloGold Ashanti Limited  AU   Catabasis Pharmaceuticals  Inc   CATB   CEL SCI Corporation  CVM   Corindus Vascular Robotics  Inc   CVRS   Everbridge  Inc   EVBG   Bitcoin Investment Trust  GBTC   the Direxion Daily Jr Gld Mnrs Bull 3X ETF  JNUG   Kirkland Lake Gold Ltd   KL   the Direxion Daily Gold Miners Bull 3X ETF  NUGT   PaySign  Inc   PAYS   PG E Corporation  PCG   uniQure N V   QURE   Sea Limited  SE   Tilray  Inc   TLRY   and Vuzix Corporation  VUZI  
Watch Video Here ",2019-06-20,Harry Boxer,https://www.investing.com/analysis/arql-cvm-evbg-jnug-kl-tlry--stock-charts-to-watch-200433491,200433491
4291,225806,ARQL,Wall Street drops as tariff deadline looms,news,"By Shreyashi Sanyal
 Reuters    Wall Street s main indexes fell in afternoon trading on Monday  with investors keeping a close watch on U S  China trade relations as planned tariffs on Chinese imports kick in on Dec  15 
Beijing and Washington are negotiating a first phase trade deal aimed at de escalating tariff disputes but they continue to wrangle over key details 
Analysts said markets are still hoping for a delay in the deadline  while expecting more positive gestures from both sides  but a lack of fresh update on trade talks sapped risk appetite 
 There is optimism about the potential of a roll back or some positive news on trade that is keeping stocks where they are   said Randy Frederick  vice president of trading and derivatives for  Charles Schwab   NYSE SCHW  in Austin  Texas 
 But as always it ultimately depends on what we get from President Donald Trump or China on what might be going on with the trade deal  
The latest data from China showed exports in November shrank for the fourth consecutive month  underscoring persistent pressures on manufacturers from trade tensions 
The S P 500 came within striking distance of a record high hit two weeks ago  The three indexes are now less than 1  away from their all time highs 
The Dow Jones Industrial Average  DJI  was down 75 84 points  or 0 27   at 27 939 22  the S P 500  SPX  was down 4 02 points  or 0 13   at 3 141 89 
The Nasdaq Composite  IXIC  was down 12 54 points  or 0 14   at 8 643 99 
CMC Markets analyst David Madden said   The common theme today is low volatility and small trading ranges but the uncertainty surrounding trade is hanging over equities  
Also in focus is the Federal Open Market Committee s two day policy meeting  which starts on Tuesday 
3M Co  N MMM  fell 0 7  after  Citigroup   NYSE C  cut its rating on the industrial conglomerate s shares 
Apple  NASDAQ AAPL  suppliers  Qorvo Inc   O QRVO  and  Skyworks Solutions Inc   O SWKS  rose about 2  each  after Bank of America Merrill Lynch  NYSE BAC  upgraded shares of both companies 
 Merck   Co   N MRK  dipped 0 2  after the drugmaker said it would buy cancer drug developer  ArQule  Inc  O ARQL  for  2 7 billion in cash  Shares of ArQule doubled in value following the news 
Advancing issues outnumbered decliners by a 1 17 to 1 ratio on the NYSE  Declining issues outnumbered advancers for a 1 13 to 1 ratio on the Nasdaq 






The S P index recorded 23 new 52 week highs and one new low  while the Nasdaq recorded 80 new highs and 44 new lows ",2019-12-09,Reuters,https://www.investing.com/news/stock-market-news/wall-street-set-to-drop-after-weak-chinese-data-tariff-deadline-looms-2036793,2036793
4297,225812,ARQL,ArQule  ARQL  In Focus  Stock Moves 6 2  Higher,opinion,ArQule  Inc    NASDAQ ARQL   was a big mover last session  as the company saw its shares rise more than 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This reverses the recent trend for the company as the stock is now down 16 4  in the past one month time frame The move came after the company announced that the first patient was dosed in registrational MOSIAC trial of Miransertib for the treatment of proteus syndrome and PIK3CA related overgrowth spectrum The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future ArQule currently has a Zacks Rank  3  Hold  while its  is positive ArQule  Inc  Price   Investors interested in the Medical   Drugs industry may consider a better ranked stock like KemPharm  Inc    NASDAQ KMPH    which carries a Zacks Rank  1  Strong Buy   You can see  Is ARQL going up  Or down  Predict to see what others think Up or DownBiggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 7 stocks to watch  The report is only available for a limited time ,2019-10-02,Zacks Investment Research,https://www.investing.com/analysis/arqule-arql-in-focus-stock-moves-62-higher-200470361,200470361
4298,225813,ARQL,Merger Monday  Biotech Edition  MRK  SNY  ARQL  THOR   More,opinion,"Monday  December 9  2019We start another trading week with some important company mergers and acquisitions activity  commonly known as  Merger Monday   In this particular Monday s case  large cap pharmaceutical companies are putting their assets to work in the biotech space  particularly in cancer treatment  oncology  First  New Jersey based Merck   Co    NYSE MRK   has agreed to purchase Massachusetts based ArQule   NASDAQ ARQL   for around  2 7 billion  or  20 per share  ArQule s lead candidate in development  it currently has no drugs on the market  is an oral BTK inhibitor  which Merck intends to help flesh out its oncology portfolio  Shares of ArQule have shot up 100  on the news   even after the company had posted gains of 235   year to date  The close of this deal is expected in the first quarter of 2020 Parisian pharma giant Sanofi   NASDAQ SNY   has also gotten into the biotech cancer treatment act today  agreeing to buy SoCal s Synthorx   NASDAQ THOR    an immuno oncology firm with a lead candidate that treats solid tumors  Sanofi sees plenty of potential here  and is paying  2 5 billion  or  68 per share  this marks a 172  premium from Friday s closing price  and pre market trading has THOR up 168  at this hour Finally  a deadline extension was granted by Swiss pharma major Roche   OTC RHHBY   in its pursuit of biotech company Spark Therapeutics   NASDAQ ONCE    The original deadline for the offer of  114 50 per share was originally scheduled for tomorrow  that s now been pushed to a week from today  December 16th  Roche was to give additional time for regulators the U S  Federal Trade Commission and the U K  Competition   Markets Authority  Spark shares jumped way back in late February when news of this deal first broke  also at the  114 50 share buying price Mark VickerySenior Editor
The Hottest Tech Mega Trend of All
Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/merger-monday-biotech-edition-mrk-sny-arql-thor--more-200491224,200491224
4299,225814,ARQL,Week Begins With Biotech Mergers,opinion,We start another trading week with some important company mergers and acquisitions activity  commonly known as  Merger Monday   In this particular Monday s case  large cap pharmaceutical companies are putting their assets to work in the biotech space  particularly in cancer treatment  oncology  First  New Jersey based Merck   Co    NYSE MRK   has agreed to purchase Massachusetts based ArQule   NASDAQ ARQL   for around  2 7 billion  or  20 per share  ArQule s lead candidate in development  it currently has no drugs on the market  is an oral BTK inhibitor  which Merck intends to help flesh out its oncology portfolio  Shares of ArQule have shot up 100  on the news   even after the company had posted gains of 235   year to date  The close of this deal is expected in the first quarter of 2020 Parisian pharma giant Sanofi  PA SASY    NASDAQ SNY   has also gotten into the biotech cancer treatment act today  agreeing to buy SoCal s Synthorx   NASDAQ THOR    an immuno oncology firm with a lead candidate that treats solid tumors  Sanofi sees plenty of potential here  and is paying  2 5 billion  or  68 per share  this marks a 172  premium from Friday s closing price  and pre market trading has THOR up 168  at this hour Finally  a deadline extension was granted by Swiss pharma major Roche   OTC RHHBY   in its pursuit of biotech company Spark Therapeutics   NASDAQ ONCE    The original deadline for the offer of  114 50 per share was originally scheduled for tomorrow  that s now been pushed to a week from today  December 16th  Roche was to give additional time for regulators the U S  Federal Trade Commission and the U K  Competition   Markets Authority  Spark shares jumped way back in late February when news of this deal first broke  also at the  114 50 share buying price ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/week-begins-with-biotech-mergers-200491217,200491217
4300,225815,ARQL,Pharma M As Continue  Merck  Sanofi To Buy Cancer Drug Firms,opinion,The year so far has proved to be M A rich as far as the drug biotech sector is concerned  There were two mega merger announcements  Bristol Myers Squibb Celgene and AbbVie Allergan  after relatively dried up M A activity in 2018  Smaller biotech research firms investigating new therapies and interesting pipeline candidates garnered attention of bigger players this year  Given that it takes several years and millions of dollars to develop new therapeutics from scratch  large pharmaceutical companies  sitting on huge piles of cash  prefer to buy innovative small mid cap biotech companies to build out their pipelines  Fast growing and lucrative markets such as oncology and gene therapy have mainly been the focus areas for M A activities Some of these buyouts came at significantly high premiums  Continuing the trend  on Monday  two of the biggest drug giants  Merck   NYSE MRK   and Sanofi   NASDAQ SNY   offered hefty premiums to buy small cancer drugmakers to strengthen their oncology pipelines On the one hand  Sanofi announced a definitive deal to buy California based small cancer biotech     NASDAQ THOR   for  68 per share in cash  representing an aggregate equity value of approximately  2 5 billion  The offer price of  68 per share represents a premium of almost 172  to Synthorx s Friday s closing price of  25 03 Merck  on the other hand  has offered to pay  20 per share in cash for an approximate total equity value of  2 7 billion to buy Massachusetts based ArQule  Inc    NASDAQ ARQL    The offer price of  20 represents a premium of almost 107  to ArQule s closing price of  9 66 per share on Friday The acquisitions  if successfully closed  will add promising cancer treatments to Sanofi and Merck s respective portfolios Sanofi s deal will add Synthorx s lead pipeline asset  THOR 707 to its immuno oncology   IO   portfolio  THOR 707 is being evaluated across multiple solid tumor types alone and in combination with immune checkpoint inhibitors  Once acquired  it can be evaluated in combination with Sanofi s present oncology medicines as well as immuno modulatory agents in pipeline  Meanwhile  the acquisition will also boost Sanofi s pipeline with Synthorx s pre clinical candidates for oncology and autoimmune disorders Meanwhile  the acquisition of ArQule will strengthen Merck s oncology pipeline with the addition of some strategic assets including  ARQ 531  its novel  oral Bruton s tyrosine kinase  BTK  inhibitor  ARQ 531 is currently being evaluated in a phase II dose expansion study for the treatment of B cell malignancies  In early stage studies  ARQ 531 has demonstrated early signs of anti tumor activity for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia  CLL  and Richter s Transformation  It has also shown a manageable safety profile While shares of ArQule were up almost 104  on Monday  Synthorx shot up almost 171   Shares of Merck and Sanofi have risen a respective 16 1  and 4 3  this year so far compared with the  increase of 7 2    Both the transactions are expected to be closed in the first quarter of next year The hefty premiums paid by Merck Sanofi clearly highlight the need of these biggies to beef up their pipelines to fight competition and sloppy sales of mature drugs due to pricing pressure and generic biosimilar competition  Smaller acquisitions like these reduce the reliance of Merck and Sanofi on their main top line drivers and blockbuster medicines  PD L1 inhibitor Keytruda for Merck and eczema treatment  Dupixent for Sanofi While Merck currently carries a Zacks Rank  2  Buy   Sanofi has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/pharma-mas-continue-merck-sanofi-to-buy-cancer-drug-firms-200491467,200491467
4303,225818,ARQL,Company News For Dec 10  2019,opinion,Shares of ArQule  Inc    NASDAQ ARQL   jumped 103 9  after Merck   Co   Inc  said it would buy the company in a deal worth  2 7 billion Shares of Synthorx  Inc    NASDAQ THOR   soared 170 5  after Sanofi  PA SASY  SA said that it will acquire the company for an aggregated equity value of around  2 5 billionShares of Canopy Growth Corporation   NYSE CGC   rose 14 2  after the company announced David Klein as the new CEOShares of Fate Therapeutics  Inc    NASDAQ FATE   rose 41 3  after the company announced positive preliminary data from its FT596 study,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-dec-10-2019-200491519,200491519
4307,225822,ARQL,Merck To Buy ArQule For  2 7B To Boost Cancer Portfolio,opinion,Merck   Co   Inc    NYSE MRK   announced that it has entered into a definitive agreement to acquire Massachusetts based small biopharmaceutical company ArQule  Inc    NASDAQ ARQL   for  2 7 billion to boost its oncology portfolio  Under the terms of the deal  Merck has offered to buy all outstanding shares of ArQule for  20 per share in cash  representing a premium of almost 104  to the latter s Friday closing price of  9 66 The acquisition of ArQule will strengthen Merck s oncology pipeline with the addition of some strategic assets including ARQ 531 ArQule s lead pipeline candidate ARQ 531  an oral BTK inhibitor  is currently being evaluated in phase II dose expansion study for the treatment of B cell malignancies  In early clinical studies  the candidate demonstrated a manageable safety profile and showed signs of anti tumor activity for treating patients with relapsed refractory chronic lymphocytic leukemia  CLL  and Richter s Transformation ArQule has several other pipeline candidates in early stage development for addressing various types of indications  mainly cancer The deal is expected to close in the first quarter of 2020  With this acquisition  Merck is looking to further diversify its oncology portfolio with expansion into targeted therapies that treat hematological malignancies Shares of Merck have rallied 16 1  so far this year  outperforming the  increase of 7 2  If the buyout gets through  this will be the fourth company to be acquired by Merck in little more than a year  In 2019  the company already purchased Peloton  NASDAQ PTON   Immune Design and Tilos to brace its cancer pipeline On Monday  French pharma giant Sanofi   NASDAQ SNY   also announced a definitive agreement to acquire small cancer biotech Synthorx  Inc  for  2 5 billion to drive its immuno oncology portfolio  This takeover deal also saw a hefty premium of more than 170  offered by Sanofi to acquire all the outstanding shares of Synthorx for  68 per share  Fridays  closing price  25 03  in cash We remind investors that the current year already witnessed a flurry of M A deal announcements including the two mega merger declarations of Bristol Myers Squibb   NYSE BMY   Celgene and AbbVie Allergan Zacks RankMerck currently carries a Zacks Rank  2  Buy   You can  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/merck-to-buy-arqule-for-27b-to-boost-cancer-portfolio-200491569,200491569
4312,225827,ARQL,Biotech ETFs Hit New Highs On Deal Activities,opinion,The healthcare space is witnessing an M A wave lately and has reached a record  342 billion in deal activity so far this year  This represents the best year by total deal value since tracking began in the 1990s  according to data provided by Dealogic  The strong rally was driven by AbbVie s   NYSE ABBV   proposed  63 billion buyout of Allergan   NYSE AGN   and Amgen s   NASDAQ AMGN    13 4 billion purchase of psoriasis and psoriatic arthritis drug Otezla from Celgene  NASDAQ CELG    which is in the process of being acquired by Bristol Myers Squibb s   NYSE BMY   The latest to jump on the M A bandwagon are Merck   Co    NYSE MRK   and Sanofi   NASDAQ SNY   that agreed to buy smaller cancer drug makers ArQule   NASDAQ ARQL   and Synthorx   NASDAQ THOR    respectively  read  A Guide to Biotech ETF Investing  Merck ArQule DealThe U S  drug giant will acquire a cancer treating biopharmaceutical company ArQule for  2 7 billion in order to tap into the drug developer s experimental blood cancer therapy that targets genetic mutations  Under the terms of the deal  Merck will pay  20 per share to ArQule stockholders  The offer represents more than a 100  premium to ArQule s closing price on Dec 6 The transaction  pending regulatory and shareholder approval  is expected to close early in the first quarter of 2020  It will strengthen Merck s oncology business before its blockbuster cancer drug Keytruda loses its market exclusivity in 2028 The news has pushed ArQule s stock more than 100   read    Sanofi Synthorx DealThe French drug giant will acquire Synthorx  which focuses on cancer and autoimmune disorder treatments  for  2 5 billion to boost its immuno oncology portfolio  Per the deal terms  Sanofi has offered to acquire all the outstanding shares of Synthorx for  68 per share in cash  a premium of about 172  to the latter s closing price on Dec 6 The deal  approved by the board of directors of both the companies but awaiting antitrust approval  is expected to close in the first quarter of 2020 THOR shares skyrocketed more than 170  on the deal news ETFs in FocusFollowing the new deals in the healthcare space  a few biotech ETFs hit new highs on the day  Below  we have highlighted them in detail below  see    Virtus LifeSci Biotech Clinical Trials ETF   ASX BBC  This fund invests solely in firms with promising drugs in clinical human trials that have not yet been approved by the FDA or gone into production  This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index  BBC has amassed  29 9 million in its asset base and charges 79 bps in fees per year from investors  It trades in a light average daily volume of around 5 000 shares and holds 96 securities in its basket with equal weight exposure each  The product carries a Zacks ETF Rank  3  Hold  with a High risk outlook  read     ALPS Medical Breakthroughs ETF   SI SBIO  This product invests in stocks of mid cap and small cap companies in the biotech sector with a market capitalization of no less than  200 million and no more than  5 billion  It follows the S Network Medical Breakthroughs Index  The product charges 50 basis points in fees per year from investors and trades in a moderate average daily volume of about 34 000 shares  It has AUM of  206 7 million in its asset base and has a Zacks ETF Rank  3 with a High risk outlook Global X Genomics   Biotechnology ETF   NYSE G  This is a new entrant in the space having accumulated  19 4 million since its inception on Apr 5  It seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science  These are companies involved in gene editing  genomic sequencing  genetic medicine therapy  computational genomics and biotechnology  The product follows the Solactive Genomics Index  charging 68 bps in annual fees  It holds 41 stocks in its basket and trades in average daily volume of 4 000 shares  read    The Cancer Immunotherapy ETF This ETF offers exposure to a basket of companies that develop therapies to treat cancer by harnessing the body s own immune system  Holding 26 stocks in its basket  it has AUM of  38 9 million and trades in average daily volume of 10 000 shares  The product charges 79 bps in annual fees and has a Zacks ETF Rank  3 with a High risk outlook iShares Nasdaq Biotechnology ETF This fund provides exposure to 215 U S  biotechnology and pharmaceutical companies by tracking the Nasdaq Biotechnology Index  IBB is the most popular fund is the biotech space with AUM of  7 7 billion and average daily volume of 2 4 million shares  Expense ratio comes in at 0 47   The product has a Zacks ETF Rank  2  Buy  with a High risk outlook  read    SPDR S P Biotech  NYSE XBI  ETF With AUM of  4 4 billion  XBI provides equal weight exposure of around 2  across 115 biotechnology stocks by tracking the S P Biotechnology Select Industry Index  It has 0 35  in expense ratio and trades in an average daily volume of 4 5 million shares  The fund has a Zacks ETF Rank  2 with a High risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-hit-new-highs-on-deal-activities-200491557,200491557
14138,235653,ARQL,ArQule and XBiotech among healthcare gainers  Precision BioSciences leads the losers,news,"Gainers  Synthorx  NASDAQ THOR   170   ArQule  NASDAQ ARQL   103   XBiotech  NASDAQ XBIT   80   Forty Seven  NASDAQ FTSV   74   Aptose Biosciences  NASDAQ APTO   41  
Losers  Precision BioSciences  NASDAQ DTIL   42   Diplomat Pharmacy  NYSE DPLO   32   ObsEva  NASDAQ OBSV   14   IMAC Holdings  NASDAQ IMAC   12   Neurotrope  NASDAQ NTRP   11  ",2019-12-09,Seeking Alpha,https://invst.ly/o-8vs,2037046
